

## PA Criteria

|                                     |                                                                                                                                                                                                                                                           |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ABIRATERONE                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ABIRATERONE ACETATE, ABIRTEGA                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Node-positive (N1), non-metastatic (M0) prostate cancer, very-high-risk prostate cancer, non-metastatic high-risk prostate cancer, non-metastatic prostate cancer with prostate-specific antigen (PSA) persistence/recurrence after radical prostatectomy |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | ACITRETIN                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ACITRETIN                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Prevention of non-melanoma skin cancers in high risk individuals, Lichen planus, Keratosis follicularis (Darier Disease)                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For psoriasis: The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate or cyclosporine.                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | ACTIMMUNE                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ACTIMMUNE                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Mycosis fungoides, Sezary syndrome                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                               |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | AIMOVIG                                                                                                                                                                                       |
| <b>Drug Names</b>                   | AIMOVIG                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For preventive treatment of migraine, continuation: The patient received at least 3 months of treatment with the requested drug and had a reduction in migraine days per month from baseline. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Initial: 3 months, Continuation: Plan Year                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | AKEEGA                                                                                                                                                                                        |
| <b>Drug Names</b>                   | AKEEGA                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                             |
| <b>Required Medical Information</b> | The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | ALBENDAZOLE                                                                                                                                                                                   |
| <b>Drug Names</b>                   | ALBENDAZOLE                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                             |
| <b>Off-label Uses</b>               | Ascariasis, trichuriasis, microsporidiosis                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Hydatid disease, Microsporidiosis: 6 months, All other indications: 1 month                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ALDURAZYME                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | ALDURAZYME                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For mucopolysaccharidosis I (MPS I): Diagnosis was confirmed by an enzyme assay demonstrating a deficiency of alpha-L-iduronidase enzyme activity and/or by genetic testing. Patients with Scheie form (i.e., attenuated MPS I) must have moderate to severe symptoms.                                                                    |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | ALECENSA                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | ALECENSA                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), brain metastases from ALK-positive NSCLC, ALK-positive anaplastic large-cell lymphoma (ALCL), Erdheim-Chester Disease (ECD) with ALK-fusion, inflammatory myofibroblastic tumors (IMT) with ALK translocation, ALK-positive large B-cell lymphoma |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or metastatic OR 2) the requested drug will be used as adjuvant treatment following tumor resection.                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ALOSETRON                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ALOSETRON HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For severe diarrhea-predominant irritable bowel syndrome (IBS): 1) The requested drug is being prescribed for a biological female or a person that self-identifies as a female, 2) chronic IBS symptoms lasting at least 6 months, 3) gastrointestinal tract abnormalities have been ruled out, AND 4) inadequate treatment response to one conventional therapy (e.g., antispasmodics, antidepressants, antidiarrheals). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | ALPHA1-PROTEINASE INHIBITOR                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ARALAST NP, PROLASTIN-C, ZEMAIRA                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For alpha1-proteinase inhibitor deficiency: Patient must have 1) clinically evident emphysema, AND 2) pretreatment serum alpha1-proteinase inhibitor level less than 11 micromol/L (80 milligrams per deciliter [mg/dL] by radial immunodiffusion or 50 mg/dL by nephelometry).                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | ALUNBRIG                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | ALUNBRIG                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), brain metastases from ALK-positive NSCLC, inflammatory myofibroblastic tumors (IMT) with ALK translocation, Erdheim-Chester disease (ECD) with ALK-fusion                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or metastatic, AND 2) the disease is anaplastic lymphoma kinase (ALK)-positive.                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ALVAIZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ALVAIZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For chronic or persistent immune thrombocytopenia (ITP) (new starts): 1) Patient (pt) has experienced an inadequate treatment response or is intolerant to a prior therapy such as corticosteroids or immunoglobulins, AND 2) Untransfused platelet (plt) count at any point prior to the initiation of the requested medication is less than 30,000/mcL OR 30,000-50,000/mcL with symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a medical or dental procedure where blood loss is anticipated, comorbidities such as peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle that predisposes pt to trauma). For ITP (continuation): plt count response to the requested drug: 1) Current plt count is less than or equal to 200,000/mcL, OR 2) Current plt count is greater than 200,000/mcL to less than or equal to 400,000/mcL and dosing will be adjusted to a plt count sufficient to avoid clinically important bleeding. For thrombocytopenia associated with chronic hepatitis C (new starts): the requested drug is used for initiation and maintenance of interferon-based therapy. For thrombocytopenia associated with chronic hepatitis C (continuation): pt is receiving interferon-based therapy. For severe aplastic anemia (AA) (new starts): Pt had an insufficient response to immunosuppressive therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | HCV: 6mo, ITP/AA initial: 6mo, ITP reauth: Plan Year, AA reauth: APR-Plan Year, IPR-16 wks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | For severe AA (continuation): 1) Current plt count is 50,000-200,000/mcL, OR 2) Current plt count is less than 50,000/mcL and pt has not received appropriately titrated therapy for at least 16 weeks, OR 3) Current plt count is less than 50,000/mcL and pt is transfusion-independent, OR 4) Current plt count is greater than 200,000/mcL to less than or equal to 400,000/mcL and dosing will be adjusted to achieve and maintain an appropriate target plt count. APR: adequate platelet response (greater than 50,000/mcL), IPR: inadequate platelet response (less than 50,000/mcL).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ALYFTREK                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | ALYFTREK                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For cystic fibrosis: the requested drug will not be used in combination with other CFTR (cystic fibrosis transmembrane conductance regulator) potentiating agents (e.g., ivacaftor, deutivacaftor).                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | 6 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | AMBRISANTAN                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | AMBRISANTAN                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | AMPHETAMINES                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | AMPHETAMINE/DEXTROAMPHETA                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) OR 2) The patient has a diagnosis of narcolepsy confirmed by a sleep study.                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ARCALYST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ARCALYST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Prevention of gout flares in patients initiating or continuing urate-lowering therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For prevention of gout flares in patients initiating or continuing urate-lowering therapy (e.g., allopurinol) (new starts): 1) two or more gout flares within the previous 12 months, AND 2) inadequate response, intolerance, or contraindication to maximum tolerated doses of a non-steroidal anti-inflammatory drug (NSAID) and colchicine, AND 3) concurrent use with urate-lowering therapy. For prevention of gout flares in patients initiating or continuing urate-lowering therapy (e.g., allopurinol) (continuation): 1) patient must have achieved or maintained a clinical benefit (i.e., a fewer number of gout attacks or fewer flare days) compared to baseline, AND 2) continued use of urate-lowering therapy concurrently with the requested drug. For recurrent pericarditis: patient must have had an inadequate response, intolerance, or contraindication to maximum tolerated doses of a NSAID and colchicine. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prior Authorization Group</b>    | ARIKAYCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ARIKAYCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                             |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ARMODAFINIL                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ARMODAFINIL                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For excessive sleepiness associated with narcolepsy: The diagnosis has been confirmed by sleep lab evaluation. For excessive sleepiness associated with obstructive sleep apnea (OSA): The diagnosis has been confirmed by polysomnography. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | AUGTYRO                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | AUGTYRO                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | AUSTEDO                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | AUSTEDO, AUSTEDO XR, AUSTEDO XR PATIENT TITRAT                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Tourette's syndrome                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | AUVELITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | AUVELITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For Major Depressive Disorder (MDD): The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | AYVAKIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | AYVAKIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Myeloid and lymphoid neoplasms with eosinophilia, gastrointestinal stromal tumor (GIST) for residual, unresectable, tumor rupture, or recurrent/metastatic disease without platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For myeloid and lymphoid neoplasms with eosinophilia, the patient meets all of the following criteria: 1) The disease is FIP1L1- PDGFRA rearrangement-positive, AND 2) The disease harbors a PDGFRA D842V mutation, AND 3) The disease is resistant to imatinib. For GIST, the patient meets either of the following criteria: 1) The disease harbors PDGFRA exon 18 mutation, including a PDGFRA D842V mutation, OR 2) The requested drug will be used after failure on at least two Food and Drug Administration (FDA)-approved therapies in residual, unresectable, tumor rupture, or recurrent/metastatic disease without PDGFRA exon 18 mutation. For systemic mastocytosis: 1) The patient has a diagnosis of indolent systemic mastocytosis or advanced systemic mastocytosis (including aggressive systemic mastocytosis [ASM], systemic mastocytosis with associated hematological neoplasm [SM-AHN], and mast cell leukemia [MCL]) AND 2) The patient has a platelet count of greater than or equal to 50,000/microliter (mcL). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

**Prior Authorization Group****Drug Names**

B VS. D

ABELCET, ACETYLCYSTEINE, ACYCLOVIR SODIUM, ALBUTEROL SULFATE, AMPHOTERICIN B, AMPHOTERICIN B LIPOSOME, APREPITANT, ASTAGRAF XL, AZACITIDINE, AZATHIOPRINE, BENDAMUSTINE HYDROCHLORID, BENDEKA, BUDESONIDE, CALCITONIN-SALMON, CALCITRIOL, CARBOPLATIN, CINACALCET HYDROCHLORIDE, CISPLATIN, CLINIMIX 4.25%/DEXTROSE 1, CLINIMIX 4.25%/DEXTROSE 5, CLINIMIX 5%/DEXTROSE 15%, CLINIMIX 5%/DEXTROSE 20%, CLINIMIX 6/5, CLINIMIX 8/10, CLINIMIX 8/14, CLINISOL SF 15%, CLINOLIPID, CROMOLYN SODIUM, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE MONOHYDR, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYTARABINE AQUEOUS, DEXTROSE 50%, DEXTROSE 70%, DIPHTHERIA/TETANUS TOXOID, DOCETAXEL, DOCIVYX, DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE, DRONABINOL, ENGERIX-B, ETOPOSIDE, EVEROLIMUS, FIASP PUMPCART, FLUOROURACIL, FRINDOVYX, FULVESTRANT, GAMASTAN, GANCICLOVIR, GEMCITABINE HCL, GEMCITABINE HYDROCHLORIDE, GENGRAF, GRANISETRON HYDROCHLORIDE, HEPARIN SODIUM, HEPLISAV-B, HUMULIN R U-500 (CONCENTR, IBANDRONATE SODIUM, IMOVAX RABIES (H.D.C.V.), INTRALIPID, IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE/ALBUT, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, JYLAMVO, JYNNEOS, KADCYLA, LEUCOVORIN CALCIUM, LEVALBUTEROL, LEVALBUTEROL HCL, LEVALBUTEROL HYDROCHLORID, LEVOCARNITINE, LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE, LIDOCAINE/PRILOCAINE, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETAT, METHYLPREDNISOLONE SODIUM, MORPHINE SULFATE, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID DR, NULOJIX, NUTRILIPID, ONDANSETRON HCL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON ODT, OXALIPLATIN, PACLITAXEL, PACLITAXEL PROTEIN-BOUND, PAMIDRONATE DISODIUM, PARICALCITOL, PEMETREXED, PENTAMIDINE ISETHIONATE, PLENAMINE, PREDNISOLONE, PREDNISOLONE SODIUM PHOSP, PREDNISONE, PREDNISONE INTENSOL, PREMASOL, PROGRAF, PROSOL, RABAVERT, RECOMBIVAX HB, SIROLIMUS, TACROLIMUS, TENIVAC, TPN ELECTROLYTES, TRAVASOL, TROPHAMINE, VINCRISTINE SULFATE, VINOELBINE TARTRATE, VIVIMUSTA, XATMEP, ZOLEDRONIC ACID

**PA Indication Indicator**

All Medically-accepted Indications

**Off-label Uses**

-

**Exclusion Criteria**

-

**Required Medical Information**

-

**Age Restrictions**

-

**Prescriber Restrictions**

-

**Coverage Duration**

N/A

**Other Criteria**

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

|                                     |                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BAFIERTAM                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | BAFIERTAM                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | BALVERSA                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | BALVERSA                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For urothelial carcinoma: 1) disease has susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, AND 2) the requested drug will be used as subsequent therapy for any of the following: a) locally advanced, recurrent, or metastatic urothelial carcinoma, OR b) stage II-IV, recurrent, or persistent urothelial carcinoma of the bladder. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | BANZEL                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | RUFINAMIDE                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | 1 year of age or older                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BENLYSTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | BENLYSTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | For patients new to therapy: severe active central nervous system lupus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For systemic lupus erythematosus (SLE): 1) patient is currently receiving a stable standard therapy regimen for SLE (for example, corticosteroid, antimalarial, or NSAIDs), OR 2) patient has experienced an intolerance or has a contraindication to standard therapy regimen for SLE. For lupus nephritis: 1) patient is currently receiving a stable standard therapy regimen for lupus nephritis (for example, corticosteroid, cyclophosphamide, mycophenolate mofetil, or azathioprine) OR 2) patient has experienced an intolerance or has a contraindication to standard therapy regimen for lupus nephritis.                                 |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | BERINERT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | BERINERT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For treatment of acute angioedema attacks due to hereditary angioedema (HAE): 1) the patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing, OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an immunologist, allergist, or rheumatologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | BESREMI                      |
| <b>Drug Names</b>                   | BESREMI                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | BETASERON                    |
| <b>Drug Names</b>                   | BETASERON                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                                                                                                                                                                |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BEXAROTENE                                                                                                                                                     |
| <b>Drug Names</b>                   | BEXAROTENE                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                              |
| <b>Off-label Uses</b>               | Mycosis fungoides (MF)/Sezary syndrome (SS), CD30-positive primary cutaneous anaplastic large cell lymphoma (ALCL), CD30-positive lymphomatoid papulosis (LyP) |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BOSENTAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | BOSENTAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) if the request is for an adult patient, the patient meets both of the following: a) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units, and b) the patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to ambrisentan (Letairis).                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | BOSULIF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | BOSULIF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL), myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I, G250E, V299L, and F317L, AND 3) Patient has experienced resistance or intolerance to imatinib, dasatinib, or nilotinib. For B-ALL including patients who have received hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I, G250E, V299L, and F317L. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BRAFTOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | BRAFTOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Adjuvant systemic therapy for cutaneous melanoma, appendiceal adenocarcinoma, recurrent NSCLC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For colorectal cancer (including appendiceal adenocarcinoma): 1) Tumor is positive for BRAF V600E mutation, AND 2) The patient has either of the following: a) advanced or metastatic disease, b) unresectable metachronous metastases. For melanoma: 1) Tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with binimetinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer (NSCLC): 1) Tumor is positive for BRAF V600E mutation, AND 2) Disease is advanced, recurrent, or metastatic, AND 3) The requested drug will be used in combination with binimetinib. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | BRIVIACT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | BRIVIACT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom (if 4 years of age or older), Xcopri (if 18 years of age or older), Spritam (if 4 years of age or older).                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | 1 month of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BRONCHITOL                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | BRONCHITOL                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | 18 years of age or older                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | BRUKINSA                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | BRUKINSA                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): the patient has experienced an intolerable adverse event or has a contraindication to Calquence (acalabrutinib). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | BUDESONIDE CAP                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | BUDESONIDE                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                |
| <b>Off-label Uses</b>               | Induction and maintenance of clinical remission of microscopic colitis in adults, autoimmune hepatitis                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For the maintenance of clinical remission of microscopic colitis: patient has had a recurrence of symptoms following discontinuation of induction therapy.                                                       |
| <b>Age Restrictions</b>             | Crohn's, treatment: 8 years of age or older                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Autoimmune hepatitis, Microscopic colitis, maintenance: 12 months, all other indications: 3 months                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | BUPRENORPHINE PATCH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | BUPRENORPHINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has taken an immediate-release opioid for at least one week. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CABOMETYX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | CABOMETYX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | Non-small cell lung cancer, Ewing sarcoma, osteosarcoma, gastrointestinal stromal tumor, endometrial carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For renal cell carcinoma: The disease is advanced, relapsed, or stage IV (including brain metastases). For non-small cell lung cancer: 1) the disease is rearranged during transfection (RET) positive AND 2) the disease is recurrent, advanced, or metastatic. For hepatocellular carcinoma: the requested drug will be used as subsequent therapy. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture, AND 2) the disease has progressed after at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib). For Ewing sarcoma and osteosarcoma: the requested drug will be used as subsequent therapy. For differentiated thyroid cancer (DTC) (follicular, papillary, oncocytic): 1) the disease is locally advanced or metastatic, AND 2) the disease has progressed after a vascular endothelial growth factor receptor (VEGFR)-targeted therapy, AND 3) the patient is refractory to radioactive iodine therapy (RAI) or ineligible for RAI. For endometrial carcinoma: 1) the disease is recurrent, AND 2) the requested drug will be used as subsequent therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prior Authorization Group</b>    | CALCIPOTRIENE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | CALCIPOTRIENE, CALCITRENE, ENSTILAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For psoriasis: The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a topical steroid.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CALQUENCE                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | CALQUENCE                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, splenic marginal zone lymphoma)                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, and splenic marginal zone lymphoma): the requested drug is being used for the treatment of relapsed, refractory, or progressive disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | CAPRELSA                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | CAPRELSA                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Thyroid carcinomas (follicular, oncocytic, papillary).                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | CARBAGLU                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | CARGLUMIC ACID                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For N-acetylglutamate synthase (NAGS) deficiency: Diagnosis of NAGS deficiency was confirmed by enzymatic, biochemical, or genetic testing.                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CAYSTON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | CAYSTON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For treatment of respiratory symptoms in cystic fibrosis patients: 1) Pseudomonas aeruginosa is present in the patient's airway cultures, OR 2) The patient has a history of pseudomonas aeruginosa infection or colonization in the airways.                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | CEQUR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | CEQUR SIMPLICITY 2U, CEQUR SIMPLICITY INSERTER                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | Initial: 1) the patient has diabetes requiring insulin management AND 2) the patient is currently self-testing glucose levels, the patient will be counseled on self-testing glucose levels, or the patient is using a continuous glucose monitor AND 3) the patient meets either of the following: a) the patient has tried bolus injections and either did not meet glycemic goals or had difficulties administering multiple insulin injections daily, b) the patient is unable to try bolus injections. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | CERDELGA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | CERDELGA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For type 1 Gaucher disease (GD1): 1) Diagnosis was confirmed by an enzyme assay demonstrating a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing, and 2) Patient's CYP2D6 metabolizer status has been established using an FDA-cleared test, and 3) Patient is a CYP2D6 extensive metabolizer, an intermediate metabolizer, or a poor metabolizer.                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CEREZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | CEREZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Type 2 Gaucher disease, Type 3 Gaucher disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For Gaucher disease: Diagnosis was confirmed by an enzyme assay demonstrating a deficiency of beta-glucocerebrosidase enzyme activity or by genetic testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | CGM LCD L33822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | DEXCOM G6 RECEIVER, DEXCOM G6 SENSOR, DEXCOM G6 TRANSMITTER, DEXCOM G7 RECEIVER, DEXCOM G7 SENSOR, FREESTYLE LIBRE 14 DAY/SE, FREESTYLE LIBRE 2/READER/, FREESTYLE LIBRE 2/SENSOR/, FREESTYLE LIBRE 3/READER/, FREESTYLE LIBRE 3/SENSOR/, FREESTYLE LIBRE/READER/FL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | To be eligible for coverage of a continuous glucose monitor (CGM) and related supplies, the beneficiary must meet all of the following initial coverage criteria (1)-(5): (1) Within six (6) months prior to ordering the CGM, the treating practitioner has an in-person or Medicare-approved telehealth visit with the beneficiary to evaluate their diabetes control and determined that criteria (2)-(5) below are met, AND (2) The beneficiary has diabetes mellitus, AND (3) The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the CGM prescribed, as evidenced by providing a prescription, AND (4) The CGM is prescribed in accordance with its FDA indications for use, AND (5) The beneficiary for whom a CGM is being prescribed, to improve glycemic control, meets at least one of the following criteria: (A) The beneficiary is insulin-treated OR (B) The beneficiary has a history of problematic hypoglycemia with documentation of at least one of the following: (I) Recurrent (more than one) level 2 hypoglycemic events (glucose less than 54mg/dL (3.0mmol/L)) that persist despite multiple (more than one) attempts to adjust medication(s) and/or modify the diabetes treatment plan OR (II) A history of one level 3 hypoglycemic event (glucose less than 54mg/dL (3.0mmol/L)) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CLOBAZAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | CLOBAZAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Seizures associated with Dravet syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | Seizures associated with Lennox-Gastaut syndrome (LGS): 2 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | CLOMIPRAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | CLOMIPRAMINE HYDROCHLORID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Depression, panic disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For obsessive-compulsive disorder (OCD) and panic disorder: The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to any of the following: a serotonin and norepinephrine reuptake inhibitor (SNRI), a selective serotonin reuptake inhibitor (SSRI). For depression: The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to two of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CLORAZEPATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | CLORAZEPATE DIPOTASSIUM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For all indications: The prescriber must acknowledge the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Short-term relief anxiety-1 month, Anxiety Disorders-4 months, All other Diagnoses-Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 65 years of age or older.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | CLOZAPINE ODT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | CLOZAPINE ODT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | COBENFY                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | COBENFY, COBENFY STARTER PACK                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For treatment of schizophrenia: 1) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | COMETRIQ                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | COMETRIQ                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Non-small cell lung cancer (NSCLC), thyroid carcinomas (follicular, oncocyctic, papillary).                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): Disease is positive for rearranged during transfection (RET) rearrangements.                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | COPIKTRA                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | COPIKTRA                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Hepatosplenic T-Cell lymphoma, breast implant-associated anaplastic large cell lymphoma (ALCL), peripheral T-Cell lymphoma                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), breast implant-associated anaplastic large cell lymphoma (ALCL), and peripheral T-Cell lymphoma: the patient has relapsed or refractory disease. For hepatosplenic T-Cell lymphoma: the patient has refractory disease.                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | COSENTYX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | COSENTYX, COSENTYX SENSOREADY PEN, COSENTYX UNOREADY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp, neck, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Pyzchiva (ustekinumab-ttwe), Skyrizi (risankizumab-rzaa), Sotyktu (deucravacitinib), Stelara (ustekinumab), Tremfya (guselkumab), Yesintek (ustekinumab-kfce). For active ankylosing spondylitis (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Rinvoq (upadacitinib), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib extended-release). For active non-radiographic axial spondyloarthritis (new starts only): patient meets any of the following: 1) patient has experienced an inadequate treatment response to a non-steroidal anti-inflammatory drug (NSAID) OR 2) patient has experienced an intolerance or has a contraindication to NSAIDs. For an adult with active psoriatic arthritis (PsA) (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Enbrel (etanercept), Humira (adalimumab), Idacio (adalimumab-aacf), Pyzchiva (ustekinumab-ttwe), Rinvoq (upadacitinib)/Rinvoq LQ (upadacitinib), Skyrizi (risankizumab-rzaa), Stelara (ustekinumab), Tremfya (guselkumab), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib extended-release), Yesintek (ustekinumab-kfce). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | For moderate to severe hidradenitis suppurativa (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following products: adalimumab-aacf, Humira (adalimumab), Idacio (adalimumab-aacf).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | COTELLIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | COTELLIC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Central nervous system (CNS) cancer (i.e., glioma, glioblastoma), adjuvant systemic therapy for cutaneous melanoma.                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For central nervous system (CNS) cancer (i.e., glioma, glioblastoma): 1) The tumor is positive for BRAF V600E activating mutation, AND 2) The requested drug will be used in combination with vemurafenib. For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used in combination with vemurafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | CYSTADROPS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | CYSTADROPS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For cystinosis: 1) Diagnosis was confirmed by ANY of the following: a) the presence of increased cystine concentration in leukocytes, OR b) genetic testing, OR c) demonstration of corneal cystine crystals by slit lamp examination, AND 2) the patient has corneal cystine crystal accumulation.                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | CYSTAGON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | CYSTAGON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For nephropathic cystinosis: Diagnosis was confirmed by ANY of the following: 1) the presence of increased cystine concentration in leukocytes, OR 2) genetic testing, OR 3) demonstration of corneal cystine crystals by slit lamp examination.                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | CYSTARAN                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | CYSTARAN                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For cystinosis: 1) Diagnosis was confirmed by ANY of the following: a) the presence of increased cystine concentration in leukocytes, OR b) genetic testing, OR c) demonstration of corneal cystine crystals by slit lamp examination, AND 2) the patient has corneal cystine crystal accumulation.                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Prior Authorization Group</b>    | DALFAMPRIDINE                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | DALFAMPRIDINE ER                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For multiple sclerosis, patient must meet the following (for new starts): prior to initiating therapy, patient demonstrates sustained walking impairment. For multiple sclerosis (continuation): patient must have experienced an improvement in walking speed OR other objective measure of walking ability since starting the requested drug. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DANZITEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | DANZITEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), pigmented villonodular synovitis/tenosynovial giant cell tumor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor for CML, patient is negative for T315I, Y253H, E255K/V, and F359V/C/I mutations. For acute lymphoblastic leukemia (ALL), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If the patient has experienced resistance to an alternative tyrosine kinase inhibitor for ALL, patient is negative for T315I, Y253H, E255K/V, F359V/C/I and G250E mutations.                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | DARAPRIM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | PYRIMETHAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Toxoplasmosis prophylaxis, Pneumocystis jirovecii pneumonia prophylaxis, cystoisosporiasis treatment and secondary prophylaxis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For primary toxoplasmosis prophylaxis and Pneumocystis jirovecii pneumonia (PCP) prophylaxis: 1) The patient has experienced an intolerance or has a contraindication to trimethoprim-sulfamethoxazole (TMP-SMX) AND 2) The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 3 months. For secondary toxoplasmosis prophylaxis: The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 6 months. For cystoisosporiasis treatment: The patient has experienced an intolerance or has a contraindication to TMP-SMX. For secondary cystoisosporiasis prophylaxis: 1) The patient has experienced an intolerance or has a contraindication to TMP-SMX AND 2) The patient has had a CD4 cell count of less than 200 cells per cubic millimeter within the past 6 months. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Congen toxo tx: Plan Yr. Acqu toxo tx, prim toxo ppx, PCP ppx: 3mo. Sec toxo ppx, cysto tx/ppx: 6mo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DAURISMO                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | DAURISMO                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Post-induction therapy/consolidation following response to previous therapy with the same regimen for acute myeloid leukemia (AML), relapsed/refractory AML as a component of repeating the initial successful induction regimen                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For acute myeloid leukemia (AML): 1) the requested drug must be used in combination with cytarabine, 2) the patient is 75 years of age or older OR has comorbidities that preclude intensive chemotherapy, AND 3) the requested drug will be used as treatment for induction therapy, post-induction/consolidation therapy, or relapsed or refractory disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | DEFERASIROX                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | DEFERASIROX                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For chronic iron overload due to blood transfusions: pretreatment serum ferritin level is greater than 1000 mcg/L.                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | DEMSER                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | METYROSINE                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to an alpha-adrenergic antagonist.                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DESMETHYLPHENIDATE                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | DESMETHYLPHENIDATE HCL, DESMETHYLPHENIDATE HYDROCHLORIDE                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Cancer-related fatigue                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) OR 2) The requested drug is being prescribed for the treatment of cancer-related fatigue after other causes of fatigue have been ruled out. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | DHE NASAL                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | DIHYDROERGOTAMINE MESYLATE                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | Coverage will be denied when used in conjunction with potent CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin).                                                                                                            |
| <b>Required Medical Information</b> | The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one triptan 5-HT <sub>1</sub> receptor agonist.                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | DIACOMIT                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | DIACOMIT                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | 6 months of age or older                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DIAZEPAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | DIAZEPAM, DIAZEPAM INTENSOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For all indications: The prescriber must acknowledge the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) For the management of anxiety disorders: 1) The requested drug is being used concurrently with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI becomes effective for the symptoms of anxiety, OR 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to AT LEAST TWO agents from the following classes: a) selective serotonin reuptake inhibitors (SSRIs), b) serotonin-norepinephrine reuptake inhibitors (SNRIs). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Short-term relief anx-1 mo, skeletal muscle spasm-3 mo, Anx Disorders-4 mo, Other Diagnoses-PlanYR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 65 years of age or older. Applies to greater than cumulative 5 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DOPTelet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | DOPTelet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For thrombocytopenia in patients with chronic liver disease: Untransfused platelet count prior to a scheduled procedure is less than 50,000/mcL. For chronic immune thrombocytopenia (ITP) (new starts): 1) Patient has experienced an inadequate treatment response or is intolerant to a prior therapy such as corticosteroids or immunoglobulins, AND 2) Untransfused platelet count at any point prior to the initiation of the requested medication is less than 30,000/mcL OR 30,000 to 50,000/mcL with symptomatic bleeding or risk factor(s) for bleeding (e.g., undergoing a medical or dental procedure where blood loss is anticipated, comorbidities such as peptic ulcer disease and hypertension, anticoagulation therapy, profession or lifestyle that predisposes patient to trauma). For ITP (continuation): platelet count response to the requested drug: 1) Current platelet count is less than or equal to 200,000/mcL, OR 2) Current platelet count is greater than 200,000/mcL and less than or equal to 400,000/mcL and dosing will be adjusted to a platelet count sufficient to avoid clinically important bleeding. |
| <b>Age Restrictions</b>             | 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Chronic liver disease: 1 month, ITP initial: 6 months, ITP continuation: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | DRIZALMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | DRIZALMA SPRINKLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Cancer pain, chemotherapy-induced neuropathic pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | 1) The patient has tried duloxetine capsules OR 2) The patient is unable to take duloxetine capsules for any reason (e.g., difficulty swallowing capsules, requires nasogastric administration).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | Generalized Anxiety Disorder: 7 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | DUPIXENT - PENDING CMS REVIEW                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | DUPIXENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For atopic dermatitis (AD), initial therapy: 1) Patient has moderate-to-severe disease, AND 2) Patient has had an inadequate treatment response to either a topical corticosteroid or a topical calcineurin inhibitor, OR topical corticosteroids and topical calcineurin inhibitors are not advisable for the patient. For AD, continuation of therapy: Patient achieved or maintained positive clinical response. For oral corticosteroid dependent asthma, initial therapy: Patient has inadequate asthma control despite current treatment with both of the following medications: 1) High-dose inhaled corticosteroid AND 2) Additional controller (i.e., long acting beta2-agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For moderate-to-severe asthma, initial therapy: Patient has a baseline blood eosinophil count of at least 150 cells per microliter and their asthma remains inadequately controlled despite current treatment with both of the following medications: 1) Medium-to-high-dose inhaled corticosteroid, AND 2) Additional controller (i.e., LABA, LAMA, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For asthma, continuation of therapy: Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For chronic rhinosinusitis with nasal polyposis (CRSwNP): 1) The requested drug is used as add-on maintenance treatment, AND 2) For 18 years of age or older, patient has experienced an inadequate treatment response to Xhance (fluticasone). |
| <b>Age Restrictions</b>             | Atopic Dermatitis: 6 months of age or older, Asthma: 6 years of age or older, Chronic Rhinosinusitis with Nasal Polyposis: 12 years of age or older, Chronic Obstructive Pulmonary Disease and Prurigo Nodularis: 18 years of age or older, Eosinophilic Esophagitis: 1 year of age or older, CSU: 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | AD, initial: 4 months, PN, initial: 6 months, CSU, initial: 6 months, All others: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

**Other Criteria**

For eosinophilic esophagitis (EoE), initial therapy: 1) Diagnosis has been confirmed by esophageal biopsy characterized by greater than or equal to 15 intraepithelial esophageal eosinophils per high power field, AND 2) Patient is exhibiting clinical manifestations of the disease (for example, dysphagia), AND 3) Patient weighs at least 15 kilograms, AND 4) Patient experienced an inadequate treatment response, intolerance, or patient has a contraindication to a topical corticosteroid. For EoE, continuation of therapy: Patient achieved or maintained a positive clinical response. For prurigo nodularis (PN), continuation of therapy: Patient achieved or maintained a positive clinical response. For chronic obstructive pulmonary disease (COPD), initial therapy: 1) Patient is either of the following: a) currently receiving standard inhaled triple therapy (i.e., inhaled glucocorticoid, LAMA, and LABA) or b) currently receiving a LAMA and LABA, and has a contraindication to inhaled glucocorticoid, AND 2) Patient has an absolute blood eosinophil count of at least 300 cells per microliter prior to initiating therapy. For COPD, continuation of therapy: Patient achieved or maintained a positive clinical response. For chronic spontaneous urticaria (CSU), initial therapy: 1) Patient has been evaluated for other causes of urticaria, including bradykinin-related angioedema and interleukin-1 (IL-1)-associated urticarial syndromes (e.g., auto-inflammatory disorders, urticarial vasculitis), 2) Patient has experienced a spontaneous onset of wheals, angioedema, or both, for at least 6 weeks, AND 3) Patient remains symptomatic despite H1 antihistamine treatment. For CSU, continuation of therapy: Patient has experienced a benefit (e.g., improved symptoms) since initiation of therapy.

**Prior Authorization Group**

ELIGARD

**Drug Names**

ELIGARD

**PA Indication Indicator**

All FDA-approved Indications, Some Medically-accepted Indications

**Off-label Uses**

Recurrent androgen receptor positive salivary gland tumors

**Exclusion Criteria**

-

**Required Medical Information**

-

**Age Restrictions**

-

**Prescriber Restrictions**

-

**Coverage Duration**

Plan Year

**Other Criteria**

-

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | EMGALITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | EMGALITY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For preventive treatment of migraine, continuation: The patient received at least 3 months of treatment with the requested drug and had a reduction in migraine days per month from baseline. For episodic cluster headache, initial: The patient experienced an inadequate treatment response, intolerance, or contraindication to a triptan 5-HT <sub>1</sub> receptor agonist. For episodic cluster headache, continuation: The patient received the requested drug for at least 3 weeks of treatment and had a reduction in weekly cluster headache attack frequency from baseline. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Initial: 3 months, Continuation: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | EMSAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | EMSAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For Major Depressive Disorder (MDD): 1) The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion OR 2) The patient is unable to swallow oral formulations.                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | ENDARI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | L-GLUTAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | 5 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | EPCLUSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | EPCLUSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Criteria will be applied consistent with current AASLD-IDSA guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | EPIDIOLEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | EPIDIOLEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | 1 year of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | EPRONTIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | EPRONTIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom (if 4 years of age or older), Xcopri (if 18 years of age or older), Spritam (if 4 years of age or older). For monotherapy treatment of primary generalized tonic-clonic seizures: 1) The patient has experienced an inadequate treatment response or intolerance to a generic topiramate immediate release product, OR 2) The patient has difficulty swallowing solid oral dosage forms (e.g., tablets, capsules). For adjunctive treatment of primary generalized tonic-clonic seizures: 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) If the patient is 6 years of age or older, the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Spritam. For the preventative treatment of migraines: 1) The patient has experienced an inadequate treatment response or intolerance to a generic topiramate immediate release product, OR 2) The patient has difficulty swallowing solid oral dosage forms (e.g., tablets, capsules). |
| <b>Age Restrictions</b>             | Epilepsy: 2 years of age or older, Migraine: 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | ERGOTAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | ERGOTAMINE TARTRATE/CAFFE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | Coverage will be denied when used in conjunction with potent CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least ONE triptan 5-HT1 agonist.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ERIVEDGE                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | ERIVEDGE                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Adult medulloblastoma                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For adult medulloblastoma: patient has received prior systemic therapy AND has tumor(s) with mutations in the sonic hedgehog pathway.                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | ERLEADA                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | ERLEADA                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | ERLOTINIB                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | ERLOTINIB HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Recurrent non-small cell lung cancer (NSCLC), recurrent chordoma, relapsed or stage IV renal cell carcinoma (RCC), brain metastases from non-small cell lung cancer (NSCLC), recurrent pancreatic cancer                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC) (including brain metastases from NSCLC): 1) the disease is recurrent, advanced, or metastatic, AND 2) the patient has sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease. For pancreatic cancer: the disease is locally advanced, unresectable, recurrent, or metastatic. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ESBRIET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | PIRFENIDONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For idiopathic pulmonary fibrosis (new starts only): 1) a high-resolution computed tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial pneumonia (UIP) pattern, OR 2) HRCT study of the chest reveals a result other than the UIP pattern (e.g., probable UIP, indeterminate for UIP) and the diagnosis is supported either by a lung biopsy or by a multidisciplinary discussion between at least a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if a lung biopsy has not been conducted. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ETANERCEPT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | ENBREL, ENBREL MINI, ENBREL SURECLICK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Hidradenitis suppurativa, non-radiographic axial spondyloarthritis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and non-radiographic axial spondyloarthritis (new starts only): patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e. at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). For hidradenitis suppurativa (new starts only): patient has severe, refractory disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | EVEROLIMUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | EVEROLIMUS, TORPENZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Classic Hodgkin lymphoma, thymomas and thymic carcinomas, previously treated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft tissue sarcoma (perivascular epithelioid cell tumors (PEComa) and lymphangioleiomyomatosis subtypes), gastrointestinal stromal tumors, neuroendocrine tumors of the thymus, well differentiated grade 3 neuroendocrine tumors, thyroid carcinoma (papillary, oncocytic, and follicular), endometrial carcinoma, uterine sarcoma, breast cancer (in combination with fulvestrant or tamoxifen), histiocytic neoplasms (Rosai-Dorfman Disease, Erdheim-Chester Disease, Langerhans Cell Histiocytosis), meningiomas.                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For breast cancer: 1) The disease is recurrent unresectable, advanced, or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, AND 2) The requested drug is prescribed in combination with exemestane, fulvestrant, or tamoxifen, AND 3) The requested drug is used for subsequent treatment. For renal cell carcinoma: The disease is relapsed, advanced, or stage IV. For subependymal giant cell astrocytoma (SEGA): The requested drug is given as adjuvant treatment. For gastrointestinal stromal tumor: 1) The disease is residual, recurrent, unresectable, or metastatic/tumor rupture, AND 2) The disease has progressed after use of at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib). For Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease, and Langerhans Cell Histiocytosis (LCH): the patient must have a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | FABRAZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | FABRAZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For Fabry disease, the patient meets ANY of the following: 1) diagnosis of Fabry disease was confirmed by an enzyme assay demonstrating a deficiency of alpha-galactosidase enzyme activity or by genetic testing, OR 2) the patient is a symptomatic obligate carrier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FANAPT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | FANAPT, FANAPT TITRATION PACK A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For treatment of schizophrenia: 1) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar. For acute treatment of manic or mixed episodes associated with bipolar I disorder: 1) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Lybalvi, Vraylar. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FASENRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | FASENRA, FASENRA PEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For severe asthma, initial therapy: 1) Either a) Patient has baseline blood eosinophil count of at least 150 cells per microliter OR b) Patient is dependent on systemic corticosteroids, AND 2) Patient has a history of severe asthma despite current treatment with both of the following medications: a) medium-to-high-dose inhaled corticosteroid AND b) additional controller (i.e., long-acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless patient has an intolerance or contraindication to such therapies. For severe asthma, continuation of therapy: Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For eosinophilic granulomatosis with polyangiitis (EGPA), initial therapy: patient has a history or the presence of an eosinophil count of more than 1000 cells per microliter or a blood eosinophil level of greater than 10 percent. For EGPA, continuation of therapy: patient has a beneficial response to treatment with the requested drug, as demonstrated by any of the following: 1) a reduction in the frequency of relapses, 2) a reduction in the daily oral corticosteroid dose, OR 3) no active vasculitis. |
| <b>Age Restrictions</b>             | Asthma: 6 years of age or older, EGPA: 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FENTANYL PATCH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | FENTANYL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has taken an immediate-release opioid for at least one week. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | FETZIMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | FETZIMA, FETZIMA TITRATION PACK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For major depressive disorder (MDD): The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to TWO of the following: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | FINTEPLA                     |
| <b>Drug Names</b>                   | FINTEPLA                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | 2 years of age or older      |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | FIRMAGON                     |
| <b>Drug Names</b>                   | FIRMAGON                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | FLUCYTOSINE                  |
| <b>Drug Names</b>                   | FLUCYTOSINE                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | 6 weeks                      |
| <b>Other Criteria</b>               | -                            |

|                                     |                                                                                                                                                               |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FOTIVDA                                                                                                                                                       |
| <b>Drug Names</b>                   | FOTIVDA                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                             |
| <b>Required Medical Information</b> | For renal cell carcinoma: 1) The disease is advanced, relapsed, refractory or Stage IV, AND 2) The patient has received two or more prior systemic therapies. |
| <b>Age Restrictions</b>             | -                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FRUZAQLA                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | FRUZAQLA                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | FULPHILA                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | FULPHILA                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | Stem cell transplantation-related indications                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | If receiving chemotherapy, the requested drug will be administered at least 24 hours after chemotherapy. For prophylaxis of myelosuppressive chemotherapy-induced febrile neutropenia: the patient must meet both of the following: 1) Patient has a solid tumor or non-myeloid cancer, AND 2) Patient is currently receiving or will be receiving treatment with myelosuppressive anti-cancer therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | 6 months                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | FYCOMPA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | FYCOMPA, PERAMPANEL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom, Xcopri, Spritam. For adjunctive treatment of primary generalized tonic-clonic seizures: 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Spritam. |
| <b>Age Restrictions</b>             | Partial-onset seizures (i.e., focal-onset seizures): 4 years of age or older. Primary generalized tonic-clonic seizures: 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | GATTEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | GATTEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For short bowel syndrome (SBS) initial therapy: 1) for an adult patient, the patient has been dependent on parenteral support for at least 12 months OR 2) for a pediatric patient, the patient is dependent on parenteral support. For SBS continuation: requirement for parenteral support has decreased from baseline while on therapy with the requested drug.                                                                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with a gastroenterologist, gastrointestinal surgeon, or nutritional support specialist.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | GAVRETO                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | GAVRETO                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Recurrent rearranged during transfection (RET) rearrangement-positive non-small cell lung cancer, RET mutation-positive medullary carcinoma                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For non-small cell lung cancer, patient must meet all of the following: 1) The disease is recurrent, advanced, or metastatic, AND 2) The tumor is rearranged during transfection (RET) fusion-positive or RET rearrangement-positive.                                                                                                                                      |
| <b>Age Restrictions</b>             | Non-small cell lung cancer: 18 years of age or older, Thyroid cancer: 12 years of age or older                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | GILENYA                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | FINGOLIMOD HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | GILOTRIF                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | GILOTRIF                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC), patient meets either of the following: 1) has sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease AND a) has experienced an intolerable adverse event or contraindication to erlotinib, gefitinib or osimertinib, OR 2) has metastatic squamous NSCLC that progressed after platinum-based chemotherapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                       |
|-------------------------------------|---------------------------------------|
| <b>Prior Authorization Group</b>    | GLATIRAMER                            |
| <b>Drug Names</b>                   | COPAXONE, GLATIRAMER ACETATE, GLATOPA |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications          |
| <b>Off-label Uses</b>               | -                                     |
| <b>Exclusion Criteria</b>           | -                                     |
| <b>Required Medical Information</b> | -                                     |
| <b>Age Restrictions</b>             | -                                     |
| <b>Prescriber Restrictions</b>      | -                                     |
| <b>Coverage Duration</b>            | Plan Year                             |
| <b>Other Criteria</b>               | -                                     |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | GOMEKLI                      |
| <b>Drug Names</b>                   | GOMEKLI                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | 2 years of age or older      |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | GROWTH HORMONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | GENOTROPIN, GENOTROPIN MINIQICK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | Pediatric patients with closed epiphyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | <p>Pediatric growth hormone deficiency (GHD): Patient (pt) is a neonate or was diagnosed with GHD as a neonate OR meets any of the following: 1) younger than 2.5 years old (yo) with pre-treatment (pre-tx) height (ht) more than 2 standard deviations (SD) below mean and slow growth velocity OR 2) 2.5 yo or older AND one of the following: a) pre-tx 1-year ht velocity more than 2 SD below mean OR b) pre-tx ht more than 2 SD below mean and 1-year ht velocity more than 1 SD below mean, AND patient meets any of the following: 1) failed 2 pre-tx growth hormone (GH) stimulation tests (peak below 10 ng/mL), OR 2) pituitary/central nervous system (CNS) disorder (e.g., genetic defects, acquired structural abnormalities, congenital structural abnormalities) and pre-tx insulin-like growth factor-1 (IGF-1) more than 2 SD below mean. Turner syndrome (TS): 1) Confirmed by karyotyping AND 2) pre-tx ht is less than the 5th percentile for age. Small for gestational age (SGA): 1) Birth weight (wt) less than 2500g at gestational age (GA) greater than 37 weeks, OR birth wt or length below 3rd percentile for GA or at least 2 SD below mean for GA, AND 2) did not manifest catch-up growth by age 2.</p> <p>SGA: 2 years of age or older</p> |
| <b>Age Restrictions</b>             | SGA: 2 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an endocrinologist, nephrologist, infectious disease specialist, gastroenterologist/nutritional support specialist, or geneticist.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | <p>Adult GHD: Pt meets any of the following: 1) failed 2 pre-tx GH stimulation tests, OR 2) pre-tx IGF-1 more than 2 SD below mean AND failed 1 pre-tx GH stimulation test, OR 3) organic hypothalamic-pituitary disease (e.g., suprasellar mass with previous surgery and cranial irradiation) with 3 or more pituitary hormone deficiencies AND pre-tx IGF-1 more than 2 SD below mean, OR 4) genetic or structural hypothalamic-pituitary defects, OR 5) childhood-onset GHD with congenital (genetic or structural) abnormality of the hypothalamus/pituitary/CNS. For pediatric GHD, TS, SGA, and adult GHD, continuation of therapy: Patient is experiencing improvement.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HAEGARDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | HAEGARDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For the prophylaxis of angioedema attacks due to hereditary angioedema (HAE): 1) the patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing, OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiotensin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month.                                              |
| <b>Age Restrictions</b>             | 6 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an immunologist, allergist, or rheumatologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | HARVONI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | HARVONI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Criteria applied consistent w/ current AASLD-IDSA guidance. Reminder for 8wk option if appropriate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HERCEPTIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | HERCEPTIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | HERCEPTIN HYLECTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | HERCEPTIN HYLECTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HERZUMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | HERZUMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HETLIOZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | TASIMELTEON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For Non-24-Hour Sleep-Wake Disorder: 1) For initial therapy and continuation of therapy the patient must meet both of the following: a) diagnosis of total blindness in both eyes (e.g., nonfunctioning retinas) and b) unable to perceive light in either eye, AND 2) If currently on therapy with the requested drug, patient must meet at least one of the following: a) increased total nighttime sleep or b) decreased daytime nap duration. For nighttime sleep disturbances in Smith-Magenis Syndrome (SMS): 1) For initial therapy and continuation therapy, the patient has a confirmed diagnosis of SMS, AND 2) If currently on therapy with the requested drug, the patient experienced improvement in the quality of sleep since starting therapy. |
| <b>Age Restrictions</b>             | Non-24: 18 years of age or older, SMS: 16 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with a sleep disorder specialist, neurologist, or psychiatrist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Initiation: 6 months, Renewal: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | HRM-ANTICONVULSANTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | PHENOBARBITAL, PHENOBARBITAL SODIUM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Epilepsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | This Prior Authorization requirement only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-ANTIPARKINSON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | BENZTROPINE MESYLATE, TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. EPS (extrapyramidal symptoms): 1) The patient has not tried the non-HRM alternative drug amantadine AND 2) The patient has a contraindication to the non-HRM alternative drug amantadine OR 3) The patient has tried the non-HRM alternative drug amantadine AND 4) The patient experienced an inadequate treatment response OR intolerance to the non-HRM alternative drug amantadine. Parkinson's: 1) The patient has tried two of the following non-HRM alternative drugs: amantadine, carbidopa/levodopa, pramipexole, or ropinirole AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following non-HRM alternative drugs: amantadine, carbidopa/levodopa, pramipexole, or ropinirole. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | HRM-CYPROHEPTADINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Pruritus, spasticity due to spinal cord injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | The prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal.                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior Authorization applies to greater than cumulative 30 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                               |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-DIPYRIDAMOLE                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | DIPYRIDAMOLE                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient.                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) |
| <b>Prior Authorization Group</b>    | HRM-GUANFACINE ER                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | GUANFACINE HYDROCHLORIDE                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient.                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) |
| <b>Prior Authorization Group</b>    | HRM-GUANFACINE IR                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | GUANFACINE HYDROCHLORIDE                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient.                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-HYDROXYZINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE PAMOATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For anxiety: 1) The patient has tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline, or venlafaxine extended-release OR 3) The patient has not tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 4) The patient has acute anxiety. For all indications: 1) Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. AND 2) If the patient is taking one or more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, cyclobenzaprine) with the requested drug, the prescriber has determined that taking multiple anticholinergic medications is medically necessary for the patient [Note: Use of multiple anticholinergic medications in older adults is associated with an increased risk of cognitive decline.]. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior authorization applies to greater than cumulative 30 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-HYDROXYZINE INJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | <p>Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. For alcohol withdrawal syndrome: 1) The patient has not tried one of the following alternative drugs: clorazepate or lorazepam AND 2) The patient has a contraindication to one of the following alternative drugs: clorazepate or lorazepam OR 3) The patient has tried one of the following alternative drugs: clorazepate or lorazepam AND 4) The patient experienced an inadequate treatment response OR intolerance to one of the following alternative drugs: clorazepate or lorazepam. For anxiety: 1) The patient has tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release OR 3) The patient has not tried two of the following alternative drugs: buspirone, duloxetine, escitalopram, sertraline or venlafaxine extended-release AND 4) The patient has acute anxiety.</p> |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-HYPNOTICS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | ESZOPICLONE, ZALEPLON, ZOLPIDEM TARTRATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For insomnia: 1) The patient meets one of the following: a) the patient has a contraindication to the non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) OR b) The non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) has been tried AND the patient experienced an inadequate treatment response OR intolerance to the non-HRM (non-High Risk Medication) alternative drug doxepin (3 mg or 6 mg) AND 2) Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient AND 3) If the patient is using two or more additional central nervous system (CNS) active medications (e.g., lorazepam, quetiapine, sertraline, clonazepam, escitalopram, alprazolam) with the requested drug, the prescriber has determined that taking multiple central nervous system (CNS) active medications is medically necessary for the patient [Note: Use of multiple central nervous system (CNS) active medications in older adults is associated with an increased risk of falls.]. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) Applies to greater than cumulative 90 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | HRM-PROMETHAZINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. For rhinitis: 1) The patient has tried two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal AND 2) The patient experienced an inadequate treatment response OR intolerance to two of the following non-HRM alternative drugs: levocetirizine, azelastine nasal, fluticasone nasal, or flunisolide nasal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior authorization applies to greater than cumulative 30 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HRM-SCOPOLAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | SCOPOLAMINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Excessive salivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.). Prior authorization applies to greater than cumulative 30 days of therapy per year.                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | HRM-SKELETAL MUSCLE RELAXANTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | CARISOPRODOL, CYCLOBENZAPRINE HYDROCHLO, METHOCARBAMOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | 1) Prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for this patient. AND 2) If the patient is using one or more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine, hydroxyzine) with the requested drug, the prescriber has determined that taking multiple anticholinergic medications is medically necessary for the patient [Note: Use of multiple anticholinergic medications in older adults is associated with an increased risk of cognitive decline.]. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 70 years of age or older. (The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) Prior authorization applies to greater than cumulative 30 days of therapy per year.                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | HUMIRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | HUMIRA, HUMIRA PEN, HUMIRA PEN-CD/UC/HS START, HUMIRA PEN-PEDIATRIC UC S, HUMIRA PEN-PS/UV STARTER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and non-radiographic axial spondyloarthritis (new starts only): patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | For non-infectious intermediate, posterior and panuveitis (new starts only): 1) patient has experienced an inadequate treatment response or intolerance to a corticosteroid OR 2) the patient has a contraindication that would prohibit a trial of corticosteroids.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IBRANCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | IBRANCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | Unresectable well-differentiated/dedifferentiated liposarcoma of the retroperitoneum, recurrent hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For breast cancer: 1) the disease is advanced, recurrent, or metastatic, AND 2) the patient has hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative disease, AND 3) the requested drug will be used in combination with an aromatase inhibitor or fulvestrant, AND 4) the patient has experienced an intolerable adverse event to Kisqali (ribociclib) OR Verzenio (abemaciclib) or has a contraindication to Kisqali (ribociclib) AND Verzenio (abemaciclib).                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | ICATIBANT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ICATIBANT ACETATE, SAJAZIR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For the treatment of acute angioedema attacks due to hereditary angioedema (HAE): 1) the patient has HAE with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing OR 2) the patient has HAE with normal C1 inhibitor confirmed by laboratory testing and one of the following: a) the patient tested positive for an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation, b) the patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month. |
| <b>Age Restrictions</b>             | 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an immunologist, allergist, or rheumatologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ICLUSIG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | ICLUSIG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Myeloid and/or lymphoid neoplasms with eosinophilia and FGFR1 or ABL1 rearrangement in the chronic phase or blast phase, Gastrointestinal Stromal Tumors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML), including patients who have received a hematopoietic stem cell transplant: 1) Patient has accelerated or blast phase CML and no other kinase inhibitor is indicated, OR 2) Patient has chronic phase CML and has experienced resistance or intolerance to at least 2 prior kinase inhibitors AND at least one of those was imatinib, dasatinib, or nilotinib, OR 3) Patient is positive for the T315I mutation. For acute lymphoblastic leukemia (ALL), including patients who have received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For gastrointestinal stromal tumors (GIST): 1) Disease meets any of the following: A) residual, B) unresectable, C) recurrent, D) metastatic/tumor rupture, AND 2) Disease has progressed after use of at least two Food and Drug Administration (FDA) approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IDACIO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | ADALIMUMAB-AACF (2 PEN), ADALIMUMAB-AACF (2 SYRING, ADALIMUMAB-AACF STARTER P, IDACIO (2 PEN), IDACIO (2 SYRINGE), IDACIO STARTER PACKAGE FO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) patient has experienced an inadequate treatment response, intolerance, or has a contraindication to methotrexate (MTX) OR 2) patient has experienced an inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis and non-radiographic axial spondyloarthritis (new starts only): patient has experienced an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR the patient has a contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, scalp, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the patient meets any of the following: a) the patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) the patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | For non-infectious intermediate, posterior and panuveitis (new starts only): 1) patient has experienced an inadequate treatment response or intolerance to a corticosteroid OR 2) the patient has a contraindication that would prohibit a trial of corticosteroids.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IDHIFA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | IDHIFA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Newly-diagnosed acute myeloid leukemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation:<br>1) patient has newly-diagnosed AML and is not a candidate for intensive induction therapy, OR 2) the requested drug will be used as post-induction therapy following response to induction therapy with the requested drug, OR 3) patient has relapsed or refractory AML.                                                                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | IMATINIB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | IMATINIB MESYLATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Desmoid tumors, pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT), recurrent chordoma, cutaneous melanoma, Kaposi sarcoma, chronic graft versus host disease (cGVHD), T-cell acute lymphoblastic leukemia with ABL-class translocation, aggressive systemic mastocytosis for well-differentiated systemic mastocytosis (WDSM) or when eosinophilia is present with FIP1L1-PDGFR fusion gene, myeloid and/or lymphoid neoplasms with eosinophilia and ABL1, FIP1L1-PDGFR, or PDGFRB rearrangement in the chronic phase or blast phase.                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including patients who have received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For CML: Patient did not fail (excluding failure due to intolerance) prior therapy with a tyrosine kinase inhibitor. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for c-KIT activating mutations AND 3) Requested medication will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IMBRUVICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | IMBRUVICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Hairy cell leukemia, lymphoplasmacytic lymphoma, primary central nervous system (CNS) lymphoma, human immunodeficiency virus (HIV)-related B-cell lymphoma, diffuse large B-cell lymphoma, post-transplant lymphoproliferative disorders, high-grade B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, splenic marginal zone lymphoma)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For mantle cell lymphoma: 1) the requested drug will be used as subsequent therapy AND the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Calquence (acalabrutinib), OR 2) the requested drug will be used in combination with rituximab as pretreatment to induction therapy with RHyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen, OR 3) the requested drug will be used as aggressive induction therapy. For marginal zone lymphoma (including extranodal marginal zone lymphoma of the stomach, extranodal marginal zone lymphoma of nongastric sites, nodal marginal zone lymphoma, and splenic marginal zone lymphoma): the requested drug will be used as second-line or subsequent therapy. For hairy cell leukemia: the requested drug will be used as a single agent for disease progression. For primary CNS lymphoma: 1) the disease is relapsed or refractory OR 2) the requested drug is used for induction therapy as a single agent. For diffuse large B-cell lymphoma, high-grade B-cell lymphoma, human immunodeficiency virus (HIV)-related B-cell lymphoma: The requested drug will be used as a single agent and as second-line or subsequent therapy for relapsed or refractory disease. For post-transplant lymphoproliferative disorders: the requested drug will be used in patients who have received prior chemoimmunotherapy. For chronic lymphocytic leukemia/small lymphocytic lymphoma: the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Calquence (acalabrutinib). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IMKELDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | IMKELDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Recurrent chordoma, cutaneous melanoma, Kaposi sarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For all indications: The patient is unable to use imatinib tablets. For chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including patients who have received a hematopoietic stem cell transplant: Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene. For CML: Patient did not fail (excluding failure due to intolerance) prior therapy with a tyrosine kinase inhibitor. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for c-KIT activating mutations AND 3) Requested medication will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | IMPAVIDO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | IMPAVIDO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | Pregnancy. Sjogren-Larsson-Syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | 28 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | INBRIJA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | INBRIJA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For initial treatment of off episodes in Parkinson's disease: 1) The patient is currently being treated with oral carbidopa/levodopa, AND 2) The patient does not have any of the following: asthma, chronic obstructive pulmonary disease (COPD), or other chronic underlying lung disease. For continuation treatment of off episodes in Parkinson's disease: The patient is experiencing improvement on the requested drug.                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | INCRELEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | INCRELEX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | Pediatric patients with closed epiphyses                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For growth failure due to severe primary insulin-like growth factor-1 (IGF-1) deficiency or growth hormone (GH) gene deletion in patients who have developed neutralizing antibodies to GH, patient meets all of the following prior to beginning therapy with the requested drug (new starts only): 1) height 3 or more standard deviations (SD) below the mean for children of the same age and gender AND 2) basal IGF-1 level 3 or more SD below the mean for children of the same age and gender AND 3) provocative growth hormone test showing a normal or elevated growth hormone level. For growth failure due to severe primary IGF-1 deficiency or GH gene deletion in patients who have developed neutralizing antibodies to GH, continuation of therapy: patient is experiencing improvement. |
| <b>Age Restrictions</b>             | 2 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an endocrinologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | INLYTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | INLYTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Thyroid carcinoma (papillary, oncocytic, or follicular), alveolar soft part sarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For renal cell carcinoma: the disease is advanced, relapsed, or Stage IV.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | INQOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | INQOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | INREBIC                                                                                                                                                          |
| <b>Drug Names</b>                   | INREBIC                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                |
| <b>Off-label Uses</b>               | Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and janus kinase 2 (JAK2) rearrangement, accelerated or blast phase myeloproliferative neoplasms |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                |
| <b>Required Medical Information</b> | For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and JAK2 rearrangement: the disease is in chronic or blast phase.                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | INSULIN SUPPLIES                                                                                                                                                 |
| <b>Drug Names</b>                   | -                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                |
| <b>Required Medical Information</b> | The requested product is being used with insulin.                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IR BEFORE ER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | HYDROCODONE BITARTRATE ER, METHADONE HCL, METHADONE HYDROCHLORIDE I, MORPHINE SULFATE ER, OXYCONTIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through palliative care OR the patient meets all of the following: 1) The requested drug is being prescribed for pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid AND 2) The patient can safely take the requested dose based on their history of opioid use [Note: This drug should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.] AND 3) The patient has been evaluated and the patient will be monitored for the development of opioid use disorder AND 4) This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days OR the patient has taken an immediate-release opioid for at least one week. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | IRESSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | GEFITINIB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or metastatic, AND 2) the patient must have a sensitizing epidermal growth factor receptor (EGFR) mutation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ISOTRETINOIN                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | ACCUTANE, AMNESTEEM, CLARAVIS, ISOTRETINOIN, ZENATANE                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Refractory acne vulgaris, severe refractory rosacea, neuroblastoma, cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), high risk for developing skin cancer (squamous cell cancers), transient acantholytic dermatosis (Grover's Disease), keratosis follicularis (Darier Disease), lamellar ichthyosis, pityriasis rubra pilaris. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | ITOVEBI                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | ITOVEBI                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ITRACONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ITRACONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Coccidioidomycosis, Coccidioidomycosis prophylaxis in HIV infection,, Cryptococcosis, Microsporidiosis, Talaromycosis (formerly Penicilliosis), Histoplasmosis prophylaxis in HIV infection, Invasive fungal infection prophylaxis in liver transplant, chronic granulomatous disease (CGD), and hematologic malignancy, Sporotrichosis, Pityriasis versicolor, Tinea versicolor, Tinea corporis, Tinea cruris, Tinea capitis, Tinea manuum, Tinea pedis, primary treatment for allergic bronchopulmonary aspergillosis, primary treatment for chronic cavitary or subacute invasive (necrotizing) pulmonary aspergillosis |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | The requested drug will be used orally. For the treatment of onychomycosis due to dermatophytes (Tinea unguium), the diagnosis has been confirmed by a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy). For primary treatment of allergic bronchopulmonary aspergillosis, the requested drug is initiated in combination with systemic corticosteroids.                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Disseminated/CNS histo, histo/CM/CGD ppx, chronic cavitary/necrotizing PA: 12 mths.<br>Others: 6 mths                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | IVERMECTIN TAB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | IVERMECTIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Ascariasis, Cutaneous larva migrans, Mansonelliasis, Scabies, Gnathostomiasis, Pediculosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | The requested drug is not being prescribed for the prevention or treatment of coronavirus disease 2019 (COVID-19).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | 1 month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | IVIG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | ALYGLO, BIVIGAM, FLEBOGAMMA DIF, GAMMAGARD LIQUID, GAMMAGARD S/D IGA LESS TH, GAMMAKED, GAMMAPLEX, GAMUNEX-C, OCTAGAM, PANZYGA, PRIVIGEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For B-cell chronic lymphocytic leukemia (CLL): 1) serum IgG less than 500 mg/dL OR 2) a history of recurrent bacterial infections. For bone marrow transplant/hematopoietic stem cell transplant (BMT/HSCT): 1) IVIG is requested within the first 100 days post-transplant OR 2) serum IgG less than 400 mg/dL. For pediatric human immunodeficiency virus (HIV) infection: 1) serum IgG less than 400 mg/dL OR 2) history of recurrent bacterial infections. For dermatomyositis and polymyositis: 1) at least one standard first-line treatment (corticosteroid or immunosuppressant) has been tried but was unsuccessful or not tolerated OR 2) patient is unable to receive standard therapy because of a contraindication or other clinical reason. For pure red cell aplasia (PRCA): PRCA is secondary to parvovirus B19 infection. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | IWILFIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | IWILFIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | JAKAFI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | JAKAFI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Lower-risk myelofibrosis, accelerated or blast phase myeloproliferative neoplasms, acute lymphoblastic leukemia (ALL), chronic myelomonocytic leukemia (CMML)-2, myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with neutrophilia, essential thrombocythemia, myeloid, lymphoid or mixed lineage neoplasms with eosinophilia and JAK2 rearrangement, T-cell prolymphocytic leukemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For polycythemia vera: 1) patient had an inadequate response or intolerance to hydroxyurea and Besremi (ropeginterferon alfa-2b-njft), OR 2) patient has high risk disease. For acute lymphoblastic leukemia: patient has a cytokine receptor-like factor 2 (CRLF2) mutation or a mutation associated with activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. For CMML-2: the requested drug is used in combination with a hypomethylating agent. For myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with neutrophilia: the requested drug is used as a single agent or in combination with a hypomethylating agent. For essential thrombocythemia: patient had an inadequate response or loss of response to hydroxyurea, interferon therapy, or anagrelide. For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and JAK2 rearrangement: the disease is in chronic or blast phase. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prior Authorization Group</b>    | JAYPIRCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | JAYPIRCA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): The patient meets both of the following: 1) The patient has received prior treatment with a Bruton Tyrosine Kinase (BTK) inhibitor, for example Calquence (acalabrutinib), AND 2) The patient has received prior treatment with a B-cell lymphoma 2 (BCL-2) inhibitor. For mantle cell lymphoma: the patient has received prior treatment for a BTK inhibitor, for example Calquence (acalabrutinib).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | KALYDECO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | KALYDECO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For cystic fibrosis (CF): The requested medication will not be used in combination with other medications containing ivacaftor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | KANJINTI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | KANJINTI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | KESIMPTA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | KESIMPTA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | KETOCONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | KETOCONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Cushing's syndrome                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | Acute or chronic liver disease. Concurrent use with drugs that are contraindicated with ketoconazole tablets: dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine, ergot alkaloids, irinotecan, lurasidone, oral midazolam, alprazolam, triazolam, felodipine, nisoldipine, tolvaptan, eplerenone, lovastatin, simvastatin, or colchicine.                          |
| <b>Required Medical Information</b> | The potential benefits outweigh the risks of treatment with oral ketoconazole. For systemic fungal infections, the patient has any of the following diagnoses: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis. For Cushing's syndrome: the requested drug is being prescribed for a patient who cannot tolerate surgery or where surgery has not been curative. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | 6 months                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | KEYTRUDA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | KEYTRUDA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                    |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | KISQALI                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | KISQALI, KISQALI FEMARA 200 DOSE, KISQALI FEMARA 400 DOSE, KISQALI FEMARA 600 DOSE                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, in combination with an aromatase inhibitor, or fulvestrant. Endometrial cancer, in combination with letrozole, for estrogen receptor positive tumors. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | KORLYM                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | MIFEPRISTONE                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an endocrinologist                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | KOSELUGO                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | KOSELUGO                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | BRAF fusion or BRAF V600E activating mutation-positive recurrent or progressive circumscribed glioma, Langerhans cell histiocytosis.                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | For neurofibromatosis type 1: 2 years of age or older                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                  |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | KRAZATI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | KRAZATI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Recurrent KRAS G12C-positive non-small cell lung cancer (NSCLC), Central nervous system (CNS) brain metastases from KRAS G12C-positive NSCLC, KRAS G12C-positive pancreatic adenocarcinoma                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | LAPATINIB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | LAPATINIB DITOSYLATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent HER2-positive breast cancer, recurrent epidermal growth factor receptor (EGFR)-positive chordoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma).                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For breast cancer, the patient meets all the following: a) the disease is recurrent, advanced, or metastatic (including brain metastases), b) the disease is human epidermal growth factor receptor 2 (HER2)-positive, c) the requested drug will be used in combination with any of the following: 1) aromatase inhibitor, 2) capecitabine, OR 3) trastuzumab. For colorectal cancer: 1) requested drug will be used in combination with trastuzumab and 2) patient has not had previous treatment with a HER2 inhibitor. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | LAZCLUZE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | LAZCLUZE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LENVIMA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | LENVIMA 10 MG DAILY DOSE, LENVIMA 12MG DAILY DOSE, LENVIMA 14 MG DAILY DOSE, LENVIMA 18 MG DAILY DOSE, LENVIMA 20 MG DAILY DOSE, LENVIMA 24 MG DAILY DOSE, LENVIMA 4 MG DAILY DOSE, LENVIMA 8 MG DAILY DOSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Medullary thyroid carcinoma, recurrent endometrial carcinoma, thymic carcinoma, unresectable or metastatic cutaneous melanoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For differentiated thyroid cancer (follicular, papillary, or oncocytic): disease is not amenable to radioactive iodine therapy and unresectable, locally recurrent, persistent, or metastatic. For hepatocellular carcinoma (HCC): disease is unresectable or inoperable, local, metastatic or with extensive liver tumor burden. For renal cell carcinoma (RCC): the disease is advanced, relapsed, or stage IV. For endometrial carcinoma (EC), the patient meets ALL of the following: 1) The disease is advanced, recurrent, or metastatic, 2) The requested drug will be used in combination with pembrolizumab, 3) The patient experienced disease progression following prior systemic therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prior Authorization Group</b>    | LEUPROLIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | LEUPROLIDE ACETATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Use in combination with growth hormone for children with growth failure and advancing puberty, recurrent androgen receptor positive salivary gland tumors, central precocious puberty                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For central precocious puberty (CPP): Patients not currently receiving therapy must meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay, 2) Assessment of bone age versus chronological age supports the diagnosis of CPP, 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients OR prior to 9 years of age for male patients.                                                                                                                                               |
| <b>Age Restrictions</b>             | CPP: Patient must be less than 12 years old if female and less than 13 years old if male                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LIDOCAINE PATCHES                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | LIDOCAINE, LIDOCAN, TRIDACAINE II                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Pain associated with diabetic neuropathy, pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g., neuropathy associated with radiation treatment or chemotherapy]).                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | LIVTENCITY                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | LIVTENCITY                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an infectious disease specialist, transplant specialist, hematologist, or oncologist.                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | 3 months                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | LONSURF                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | LONSURF                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Unresectable locally advanced, recurrent, or metastatic esophageal cancer.<br>Unresectable locally advanced or recurrent gastric cancer and gastroesophageal junction cancers. Advanced or metastatic appendiceal adenocarcinoma.                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For colorectal cancer (including appendiceal adenocarcinoma): The disease is advanced or metastatic. For gastric, esophageal, or gastroesophageal junction adenocarcinoma, ALL of the following criteria must be met: 1) The disease is unresectable locally advanced, recurrent, or metastatic, and 2) The patient has been previously treated with at least two prior lines of chemotherapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LORBRENA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | LORBRENA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Anaplastic lymphoma kinase (ALK)-positive recurrent non-small cell lung cancer (NSCLC), proto-oncogene tyrosine-protein kinase ROS1 (ROS1) rearrangement-positive recurrent, advanced, or metastatic NSCLC, symptomatic or relapsed/refractory ALK-positive Erdheim-Chester Disease, inflammatory myofibroblastic tumor (IMT) with ALK translocation (including advanced, recurrent/metastatic, or inoperable uterine sarcoma for IMT with ALK translocation), central nervous system (CNS) brain metastases from ALK rearrangement-positive NSCLC, relapsed or refractory ALK-positive Diffuse Large B-Cell Lymphoma |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For recurrent, advanced, or metastatic non-small cell lung cancer: 1) Disease is ALK-positive AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib) OR 3) Disease is positive for ROS1 rearrangement and the requested drug is being used following disease progression on crizotinib, entrectinib, or ceritinib.                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | LUMAKRAS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | LUMAKRAS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Recurrent KRAS G12C-positive non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LUMIZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | LUMIZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For Pompe disease: Diagnosis was confirmed by an enzyme assay demonstrating a deficiency of acid alpha-glucosidase (GAA) enzyme activity or by genetic testing.                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | LUPRON PED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | LUPRON DEPOT-PED (1-MONTH, LUPRON DEPOT-PED (3-MONTH, LUPRON DEPOT-PED (6-MONTH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For central precocious puberty (CPP): Patients not currently receiving therapy must meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay, AND 2) Assessment of bone age versus chronological age supports the diagnosis of CPP, AND 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients OR prior to 9 years of age for male patients. |
| <b>Age Restrictions</b>             | CPP: Patient must be less than 12 years old if female and less than 13 years old if male                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LUPRON-ENDOMETRIOSIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | LUPRON DEPOT (1-MONTH), LUPRON DEPOT (3-MONTH)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Breast cancer, ovarian cancer/fallopian tube cancer/primary peritoneal cancer, androgen receptor positive recurrent salivary gland tumor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For retreatment of endometriosis, the requested drug is used in combination with norethindrone acetate. For uterine fibroids, patient must meet one of the following: 1) diagnosis of anemia (e.g., hematocrit less than or equal to 30 percent and/or hemoglobin less than or equal to 10g/dL), OR 2) the requested medication will be used prior to surgery for uterine fibroids. For breast cancer, the requested drug is used for hormone receptor (HR)-positive disease.                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Fibroids: 3 months (mo), max 6 mo total. Endometriosis: 6 mo, max 12 mo total. Others: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | LYNPARZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | LYNPARZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent HER2-negative, BRCA 1/2-germline mutated breast cancer, recurrent or metastatic HER2-positive, BRCA 1/2-germline mutated breast cancer, uterine leiomyosarcoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For recurrent or metastatic breast cancer: the disease is BRCA 1/2-germline mutated. For prostate cancer: 1) The patient has a BRCA mutation and the requested drug will be used in combination with abiraterone and an oral corticosteroid OR 2) The patient has progressed on prior treatment with an androgen receptor-directed therapy. For ovarian, fallopian tube, or primary peritoneal cancer: The requested drug is used for maintenance therapy for stage II-IV or recurrent disease who are in complete or partial response to chemotherapy. For uterine leiomyosarcoma: 1) the patient has had at least one prior therapy AND 2) the patient has BRCA-altered disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | LYTGOBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | LYTGOBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Extrahepatic cholangiocarcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For cholangiocarcinoma: 1) patient has a diagnosis of unresectable, locally advanced or metastatic cholangiocarcinoma, 2) patient has received a previous treatment, AND 3) patient has a disease that has a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | MAVYRET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | MAVYRET                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh [CTP] class B or C).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For hepatitis C virus (HCV): Infection confirmed by presence of HCV RNA in the serum prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [CTP class B or C]), presence or absence of human immunodeficiency virus (HIV) coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Criteria will be applied consistent with current AASLD-IDSA guidance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | MEGESTROL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | MEGESTROL ACETATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Cancer-related cachexia in adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | Patient has experienced an inadequate treatment response or intolerance to megestrol 40 milligrams per milliliter (40mg/mL) oral suspension.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | MEKINIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | MEKINIST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For melanoma: 1) The tumor is positive for a BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with dabrafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For uveal melanoma: The requested drug will be used as a single agent. For ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: The requested drug will be used to treat persistent or recurrent disease. For papillary, follicular, and oncocytic thyroid carcinoma: 1) The disease is positive for BRAF V600E mutation, AND 2) The disease is not amenable to radioactive iodine (RAI) therapy, AND 3) The requested drug will be used in combination with dabrafenib. For solid tumors: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested drug will be used in combination with dabrafenib. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | MEKTOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | MEKTOVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Adjuvant systemic therapy for cutaneous melanoma, Langerhans Cell Histiocytosis, recurrent non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used in combination with encorafenib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer: 1) The tumor is positive for BRAF V600E mutation, AND 2) The requested drug will be used in combination with encorafenib, AND 3) The disease is advanced, recurrent, or metastatic.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | MEMANTINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | MEMANTINE HCL TITRATION P, MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE E                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | This prior authorization only applies to patients less than 30 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | MEPRON                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | ATOVAQUONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Babesiosis, Toxoplasmosis, Pneumocystis jirovecii pneumonia prophylaxis in pediatric patients, mild-to-moderate Pneumocystis jirovecii pneumonia treatment in pediatric patients.                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For the treatment of mild-to-moderate Pneumocystis jirovecii pneumonia (PCP): the patient had an intolerance or has a contraindication to sulfamethoxazole/trimethoprim (SMX-TMP). For the prevention of PCP and primary toxoplasmosis prophylaxis indications: 1) the patient had an intolerance or has a contraindication to SMX-TMP, AND 2) the patient is immunocompromised. For secondary toxoplasmosis prophylaxis: the patient is immunocompromised. For babesiosis treatment: the requested drug is used concurrently with azithromycin. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Secondary toxoplasmosis prophylaxis: 6 months, All other indications: 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | METHYLPHENIDATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | METHYLPHENIDATE HYDROCHLO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | 1) The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) OR 2) The patient has a diagnosis of narcolepsy confirmed by a sleep study OR 3) The requested drug is being prescribed for the treatment of cancer-related fatigue after other causes of fatigue have been ruled out.                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | METHYLTESTOSTERONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | METHYLTESTOSTERONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to alternative testosterone products (e.g., topical testosterone, transdermal testosterone, injectable testosterone). For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | MODAFINIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | MODAFINIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Idiopathic hypersomnia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For excessive sleepiness associated with narcolepsy: The diagnosis has been confirmed by sleep lab evaluation. For excessive sleepiness associated with obstructive sleep apnea (OSA): The diagnosis has been confirmed by polysomnography. For idiopathic hypersomnia, initial request, the diagnosis has been confirmed by ALL of the following: 1) Patient has experienced lapses into sleep or an irrepressible need to sleep during daytime, on a daily basis, for at least 3 months, AND 2) Insufficient sleep syndrome is confirmed absent, AND 3) Cataplexy is absent, AND 4) Fewer than 2 sleep onset rapid eye movement periods (SOREMPs) or no SOREMPs, if the rapid eye movement latency on an overnight sleep study was less than or equal to 15 minutes, AND 5) Average sleep latency of less than or equal to 8 minutes on Multiple Sleep Latency Test or total 24-hour sleep time is greater than or equal to 11 hours, AND 6) Another condition (sleep disorder, medical or psychiatric disorder, or drug/medication use) does not better explain the hypersomnolence and test results. For idiopathic hypersomnia, continuation of therapy: The patient has experienced a decrease in daytime sleepiness from baseline. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | MONJUVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | MONJUVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | HIV-related B-cell lymphoma, monomorphic post-transplant lymphoproliferative disorder (B-cell type), high-grade B-cell lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For diffuse large B-cell lymphoma (DLBCL) not otherwise specified, HIV-related B-cell lymphoma, monomorphic post-transplant lymphoproliferative disorder (B-cell type), high-grade B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) not otherwise specified including DLBCL arising from low grade lymphoma: 1) the patient has relapsed or refractory disease, AND 2) the patient is not eligible for autologous stem cell transplant (ASCT).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                           |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | MOUNJARO                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | MOUNJARO                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | NAGLAZYME                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | NAGLAZYME                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | Diagnosis of Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) was confirmed by an enzyme assay demonstrating a deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) enzyme activity or by genetic testing. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | NERLYNX                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | NERLYNX                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                         |
| <b>Off-label Uses</b>               | Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer, brain metastases from HER2-positive breast cancer.                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | NEXAVAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | SORAFENIB TOSYLATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | Acute myeloid leukemia, soft tissue sarcoma (angiosarcoma, desmoid tumors/aggressive fibromatosis, and solitary fibrous tumor subtypes), gastrointestinal stromal tumor, medullary thyroid carcinoma, osteosarcoma, recurrent chordoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, lymphoid and/or myeloid neoplasms with eosinophilia and FLT3 rearrangement in chronic or blast phase                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For acute myeloid leukemia: the disease is FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation-positive and any of the following is met :1) the requested drug will be used as maintenance therapy after hematopoietic stem cell transplant, OR 2) the requested drug is being used for low-intensity treatment induction, post-induction therapy, or consolidation therapy, OR 3) the disease is relapsed/refractory. For thyroid carcinoma: histology is follicular, papillary, oncocytic, or medullary. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture, AND 2) the disease has progressed after use of at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | NINLARO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | NINLARO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | Relapsed/refractory systemic light chain amyloidosis, Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | NITISINONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | NITISINONE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For hereditary tyrosinemia type 1 (HT-1): Diagnosis of HT-1 is confirmed by one of the following: 1) biochemical testing (e.g., detection of succinylacetone in urine) OR 2) DNA testing (mutation analysis).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | NORTHERA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | DROXIDOPA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For neurogenic orthostatic hypotension (nOH): For initial therapy, patient has a persistent, consistent decrease in systolic blood pressure of at least 20 mmHg OR decrease in diastolic blood pressure of at least 10 mmHg within 3 minutes of standing or head-up tilt test. For continuation of therapy, patient has experienced a sustained reduction in symptoms of nOH (i.e., decrease in dizziness, lightheadedness, or feeling faint). For both initial and continuation of therapy, the requested drug will be used for patients with neurogenic orthostatic hypotension associated with one of the following diagnoses: 1) primary autonomic failure due to Parkinson's disease, multiple system atrophy, or pure autonomic failure, OR 2) dopamine beta-hydroxylase deficiency, OR 3) non-diabetic autonomic neuropathy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                      |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | NOXAFIL SUSP                                                                                                                                                                                         |
| <b>Drug Names</b>                   | POSACONAZOLE                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | The requested drug will be used orally. For treatment of oropharyngeal candidiasis: patient has experienced an inadequate treatment response, intolerance, or has a contraindication to fluconazole. |
| <b>Age Restrictions</b>             | 13 years of age or older                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Oropharyngeal candidiasis: 1 month. All other indications: 6 months                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | NUBEQA                                                                                                                                                                                               |
| <b>Drug Names</b>                   | NUBEQA                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | NUEDEXTA                                                                                                                                                                                             |
| <b>Drug Names</b>                   | NUEDEXTA                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For pseudobulbar affect (PBA) (continuation): The patient has experienced a decrease in pseudobulbar affect (PBA) episodes since starting therapy with the requested drug.                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Initial: 4 months, Continuation: Plan Year                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | NUPLAZID                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | NUPLAZID                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For hallucinations and delusions associated with Parkinson's disease psychosis, the diagnosis of Parkinson's disease must be made prior to the onset of psychotic symptoms.                                                                                                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | NURTEC                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | NURTEC                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | Acute migraine treatment: The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to one triptan 5-HT1 receptor agonist. Preventive treatment of migraine, continuation: The patient received at least 3 months of treatment with the requested drug and had a reduction in migraine days per month from baseline.                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Preventive treatment of migraine, initial: 3 months, All other indications: Plan Year                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | OCTREOTIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | OCTREOTIDE ACETATE                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Tumor control of thymomas and thymic carcinomas                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly, continuation of therapy: Patient's IGF-1 level has decreased or normalized since initiation of therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ODOMZO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | ODOMZO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | OFEV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | OFEV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For idiopathic pulmonary fibrosis (new starts only): 1) a high-resolution computed tomography (HRCT) study of the chest or a lung biopsy reveals the usual interstitial pneumonia (UIP) pattern, OR 2) HRCT study of the chest reveals a result other than the UIP pattern (e.g., probable UIP, indeterminate for UIP) and the diagnosis is supported either by a lung biopsy or by a multidisciplinary discussion between at least a radiologist and pulmonologist who are experienced in idiopathic pulmonary fibrosis if a lung biopsy has not been conducted. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | OGIVRI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | OGIVRI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | OGSIVEO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | OGSIVEO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | OJEMDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | OJEMDA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For relapsed or refractory pediatric low-grade glioma (LGG): the patient's tumor is positive for either a) BRAF fusion or rearrangement OR b) BRAF V600 mutation.                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | OJJAARA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | OJJAARA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Accelerated or blast phase myeloproliferative neoplasms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For myelofibrosis, patient meets ALL of the following: 1) the patient has a diagnosis of intermediate or high-risk primary myelofibrosis or secondary myelofibrosis (i.e., post-polycythemia vera or post-essential thrombocythemia), AND 2) the patient has anemia defined as hemoglobin less than 10 grams per deciliter (g/dL) or having transfusion-dependent anemia, AND 3) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Jakafi (ruxolitinib) OR has hemoglobin less than 8 g/dL. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | OMEGA-3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | OMEGA-3-ACID ETHYL ESTERS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For hypertriglyceridemia: Prior to the start of treatment with a triglyceride lowering drug, the patient has/had a pretreatment triglyceride level greater than or equal to 500 milligram per deciliter (mg/dL).                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | OMNIPOD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | OMNIPOD 5 DEXCOM G7G6 INT, OMNIPOD 5 DEXCOM G7G6 POD, OMNIPOD 5 G7 INTRO KIT (G, OMNIPOD 5 G7 PODS (GEN 5), OMNIPOD 5 LIBRE2 PLUS G6, OMNIPOD CLASSIC PODS (GEN, OMNIPOD DASH INTRO KIT (G, OMNIPOD DASH PODS (GEN 4)                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | Initial: 1) The patient has diabetes requiring insulin management with multiple daily injections AND 2) The patient is self-testing glucose levels 4 or more times per day OR the patient is using a continuous glucose monitor AND 3) The patient has experienced any of the following with the current diabetes regimen: inadequate glycemic control, recurrent hypoglycemia, wide fluctuations in blood glucose, dawn phenomenon with persistent severe early morning hyperglycemia, severe glycemic excursions. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | OMNIPOD GO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | OMNIPOD GO 10 UNITS/DAY, OMNIPOD GO 15 UNITS/DAY, OMNIPOD GO 20 UNITS/DAY, OMNIPOD GO 25 UNITS/DAY, OMNIPOD GO 30 UNITS/DAY, OMNIPOD GO 35 UNITS/DAY, OMNIPOD GO 40 UNITS/DAY                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | Initial: 1) the patient has diabetes requiring insulin management AND 2) the patient is currently self-testing glucose levels, the patient will be counseled on self-testing glucose levels, or the patient is using a continuous glucose monitor AND 3) the patient has experienced an inadequate treatment response or intolerance to long-acting basal insulin therapy.                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ONTRUZANT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | ONTRUZANT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | All indications: the patient had an intolerable adverse event to Trazimera and that adverse event was NOT attributed to the active ingredient as described in the prescribing information. For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the disease is HER2-positive AND 2) the requested drug is used in combination with paclitaxel and continued as a single agent for maintenance therapy.                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | ONUREG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | ONUREG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Peripheral T-cell lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | OPIPZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | OPIPZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For treatment of schizophrenia, 1) the patient meets both of the following: a) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND b) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar, OR 2) The patient is unable to swallow oral formulations. For adjunctive treatment of major depressive disorder (MDD), 1) the patient meets both of the following: a) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, olanzapine, quetiapine, AND b) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Rexulti, Vraylar, OR 2) The patient is unable to swallow oral formulations. For treatment of irritability associated with autistic disorder: 1) The patient experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, risperidone, OR 2) The patient is unable to swallow oral formulations. For the treatment of Tourette's disorder: 1) The patient experienced an inadequate treatment response or intolerance to generic aripiprazole, OR 2) The patient is unable to swallow oral formulations. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | OPSUMIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | OPSUMIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ORGOVYX                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | ORGOVYX                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | ORKAMBI                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | ORKAMBI                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For cystic fibrosis (CF): The requested medication will not be used in combination with other medications containing ivacaftor.                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | 1 year of age or older                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | ORSERDU                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | ORSERDU                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Recurrent hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | Breast cancer: 1) the disease is estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2)-negative, and ESR1 mutated AND 2) the patient meets either of the following: a) the disease is advanced, recurrent, or metastatic AND the patient has disease progression following at least one line of endocrine therapy OR b) the disease had no response to preoperative systemic therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                          |
|-------------------------------------|------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | OZEMPIC                                                                                  |
| <b>Drug Names</b>                   | OZEMPIC                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                             |
| <b>Off-label Uses</b>               | -                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                        |
| <b>Required Medical Information</b> | -                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                |
| <b>Other Criteria</b>               | -                                                                                        |
| <b>Prior Authorization Group</b>    | PANRETIN                                                                                 |
| <b>Drug Names</b>                   | PANRETIN                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                        |
| <b>Off-label Uses</b>               | Topical treatment of cutaneous lesions in patients with non-AIDS-related Kaposi sarcoma  |
| <b>Exclusion Criteria</b>           | -                                                                                        |
| <b>Required Medical Information</b> | -                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                |
| <b>Other Criteria</b>               | -                                                                                        |
| <b>Prior Authorization Group</b>    | PAROXETINE SUSP                                                                          |
| <b>Drug Names</b>                   | PAROXETINE HYDROCHLORIDE                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                             |
| <b>Off-label Uses</b>               | -                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                        |
| <b>Required Medical Information</b> | The patient has difficulty swallowing solid oral dosage forms (e.g., capsules, tablets). |
| <b>Age Restrictions</b>             | -                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                |
| <b>Other Criteria</b>               | -                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | PEGASYS                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | PEGASYS                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Myeloproliferative neoplasm (essential thrombocythemia, polycythemia vera, symptomatic lower-risk myelofibrosis), systemic mastocytosis, adult T-cell leukemia/lymphoma, mycosis fungoides/sezary syndrome, primary cutaneous CD30+ T-cell lymphoproliferative disorders, hairy cell leukemia, Erdheim-Chester disease, initial treatment during pregnancy for chronic myeloid leukemia. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For chronic hepatitis C: Hepatitis C virus (HCV) confirmed by presence of hepatitis C virus HCV RNA in serum prior to starting treatment and the planned treatment regimen.                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | HCV: 12-48wks. HBV: 48wks. Other: Plan Yr                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | PEMAZYRE                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | PEMAZYRE                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | PHENYLBUTYRATE                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | SODIUM PHENYLBUTYRATE                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For urea cycle disorders (UCD): Diagnosis of UCD was confirmed by enzymatic, biochemical, or genetic testing.                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | PHESGO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | PHESGO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | PIMECROLIMUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | PIMECROLIMUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Psoriasis on the face, genitals, or skin folds.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For mild to moderate atopic dermatitis (eczema): the patient meets either of the following criteria: 1) the disease affects sensitive skin areas (e.g., face, genitals, or skin folds), OR 2) the patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first line therapy agent (e.g., medium or higher potency topical corticosteroid). For all indications: the requested drug is prescribed for short-term or non-continuous chronic use. |
| <b>Age Restrictions</b>             | 2 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | PIQRAY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | PIQRAY 200MG DAILY DOSE, PIQRAY 250MG DAILY DOSE, PIQRAY 300MG DAILY DOSE                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated breast cancer in combination with fulvestrant.                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|                                     |                                                                                                                                                                                                                                                      |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | POMALYST                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | POMALYST                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | Relapsed/refractory systemic light chain amyloidosis, primary central nervous system (CNS) lymphoma, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For multiple myeloma, patient has previously received at least two prior therapies, including an immunomodulatory agent AND a proteasome inhibitor.                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | POSACONAZOLE                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | POSACONAZOLE DR                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | The requested drug will be used orally. For prophylaxis of invasive Aspergillus and Candida infections: patient weighs greater than 40 kilograms.                                                                                                    |
| <b>Age Restrictions</b>             | Treatment of Invasive Aspergillosis: 13 years of age or older, Prophylaxis of Invasive Aspergillus and Candida Infections: 2 years of age or older                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | 6 months                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | PREGABALIN                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | PREGABALIN                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | Cancer-related neuropathic pain, cancer treatment-related neuropathic pain                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For the management of postherpetic neuralgia, the management of neuropathic pain associated with diabetic peripheral neuropathy: The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to gabapentin. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | PREVYMIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | PREVYMIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For prophylaxis of cytomegalovirus (CMV) infection or disease in hematopoietic stem cell transplant (HSCT): 1) the patient is CMV-seropositive, AND 2) the patient is a recipient of an allogeneic HSCT. For prophylaxis of CMV disease in kidney transplant: 1) the patient is CMV-seronegative, AND 2) the patient is a high risk recipient of kidney transplant.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | 7 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | PROCRIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | PROCRIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Anemia due to myelodysplastic syndromes (MDS), anemia in rheumatoid arthritis (RA), anemia due to hepatitis C treatment (ribavirin in combination with either interferon alfa or peginterferon alfa)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | Patients receiving chemotherapy with curative intent. Patients with myeloid cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | Requirements regarding hemoglobin (Hgb) values exclude values due to a recent transfusion. For initial approval: 1) for all uses except anemia due to chemotherapy or myelodysplastic syndrome (MDS): patient has adequate iron stores (for example, a transferrin saturation [TSAT] greater than or equal to 20%), AND 2) for all uses except surgery: pretreatment (no erythropoietin treatment in previous month) Hgb is less than 10 g/dL, AND 3) for MDS: pretreatment serum erythropoietin level is 500 international units/L or less. For reauthorizations (patient received erythropoietin treatment in previous month) in all uses except surgery: 1) patient has received at least 12 weeks of erythropoietin therapy, AND 2) patient responded to erythropoietin therapy, AND 3) current Hgb is less than 12 g/dL, AND 4) for all uses except anemia due to chemotherapy or MDS: patient has adequate iron stores (for example, a transferrin saturation [TSAT] greater than or equal to 20%). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | 16 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | Coverage includes use in anemia in patients whose religious beliefs forbid blood transfusions. Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual (e.g., used for treatment of anemia for a patient with chronic renal failure who is undergoing dialysis, or furnished from physician's supply incident to a physician service).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | PULMOZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | PULMOZYME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | PYZCHIVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | PYZCHIVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | QINLOCK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | QINLOCK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Gastrointestinal stromal tumor (GIST) for residual, unresectable, tumor rupture, recurrent, or progressive disease. Metastatic or unresectable cutaneous melanoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For residual, unresectable, tumor rupture, advanced, recurrent/metastatic, or progressive gastrointestinal stromal tumor (GIST): 1) Patient has received prior treatment with 3 or more kinase inhibitors, including imatinib OR 2) Patient has experienced disease progression following treatment with avapritinib and dasatinib OR 3) Patient has received prior treatment with imatinib and is intolerant of second-line sunitinib. For cutaneous melanoma: 1) Disease is metastatic or unresectable AND 2) Disease is positive for KIT activating mutations AND 3) Requested drug will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | QUETIAPINE XR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | QUETIAPINE FUMARATE ER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | Maintenance monotherapy treatment in bipolar I disorder, monotherapy treatment of generalized anxiety disorder, monotherapy treatment of major depressive disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For all indications: If the patient is 65 years of age or older AND is using two or more additional central nervous system (CNS) active medications (e.g., lorazepam, sertraline, clonazepam, escitalopram, alprazolam, zolpidem) with the requested drug, the prescriber determined that taking multiple central nervous system (CNS) active medications is medically necessary. [Note: Use of multiple central nervous system (CNS) active medications in older adults is associated with an increased risk of falls]. For treatment of schizophrenia: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine immediate-release, risperidone, ziprasidone. For acute treatment of manic or mixed episodes associated with bipolar I disorder or maintenance treatment of bipolar I disorder: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: aripiprazole, asenapine, olanzapine, quetiapine immediate-release, risperidone, ziprasidone. For acute treatment of depressive episodes associated with bipolar I disorder: The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: lurasidone, olanzapine, quetiapine immediate-release. For acute treatment of depressive episodes associated with bipolar II disorder: The patient experienced an inadequate treatment response or intolerance to generic quetiapine immediate-release. For adjunctive treatment of major depressive disorder (MDD): The patient experienced an inadequate treatment response, intolerance, or contraindication to one of the following generic products: aripiprazole, olanzapine, quetiapine immediate-release. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prior Authorization Group</b>    | QUININE SULFATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | QUININE SULFATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | Babesiosis, uncomplicated Plasmodium vivax malaria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For babesiosis: the requested drug is used in combination with clindamycin.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | 1 month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                           |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | QULIPTA                                                                                                                                                                                   |
| <b>Drug Names</b>                   | QULIPTA                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                         |
| <b>Required Medical Information</b> | Preventive treatment of migraine, continuation: The patient received at least 3 months of treatment with the requested drug and had a reduction in migraine days per month from baseline. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Initial: 3 months, Continuation: Plan Year                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | RALDESY                                                                                                                                                                                   |
| <b>Drug Names</b>                   | RALDESY                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                         |
| <b>Required Medical Information</b> | The patient is unable to swallow trazodone tablets.                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                         |
| <b>Prior Authorization Group</b>    | REGRANEX                                                                                                                                                                                  |
| <b>Drug Names</b>                   | REGRANEX                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                              |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                         |
| <b>Required Medical Information</b> | -                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | 20 weeks                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RELISTOR INJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | RELISTOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For the treatment of opioid-induced constipation in a patient with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation: 1) the patient is unable to tolerate oral medications, OR 2) the patient meets one of the following criteria: A) experienced an inadequate treatment response or intolerance to an oral drug indicated for opioid-induced constipation in a patient with chronic non-cancer pain (e.g., Movantik), OR B) the patient has a contraindication that would prohibit a trial of an oral drug indicated for opioid-induced constipation in a patient with chronic non-cancer pain (e.g., Movantik). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | REMICADE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | INFLIXIMAB, REMICADE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Behcet's syndrome, hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma gangrenosum, sarcoidosis, Takayasu's arteritis, uveitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) Pt meets ANY of the following: a) requested drug will be used in combination with methotrexate (MTX) or leflunomide OR b) intolerance or contraindication to MTX AND leflunomide, AND 2) Pt meets ANY of the following: a) inadequate treatment response, intolerance or contraindication to MTX OR b) inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis (new starts only): an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at time of diagnosis, AND 2) Pt meets ANY of the following: a) Pt has experienced inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b) pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c) Pt has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | For hidradenitis suppurativa (new starts only): Pt has severe, refractory disease. For uveitis (new starts only): Inadequate treatment response or intolerance or has a contraindication to a trial of immunosuppressive therapy for uveitis. For all indications: The patient experienced an intolerable adverse event to Renflexis and that adverse event was NOT attributed to the active ingredient as described in the prescribing information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RENFLEXIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | RENFLEXIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Behcet's syndrome, hidradenitis suppurativa, juvenile idiopathic arthritis, pyoderma gangrenosum, sarcoidosis, Takayasu's arteritis, uveitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) Pt meets ANY of the following: a) requested drug will be used in combination with methotrexate (MTX) or leflunomide OR b) intolerance or contraindication to MTX AND leflunomide, AND 2) Pt meets ANY of the following: a) inadequate treatment response, intolerance or contraindication to MTX OR b) inadequate treatment response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. For active ankylosing spondylitis (new starts only): an inadequate treatment response or intolerance to a non-steroidal anti-inflammatory drug (NSAID) OR contraindication that would prohibit a trial of NSAIDs. For moderate to severe plaque psoriasis (new starts only): 1) At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at time of diagnosis, AND 2) Pt meets ANY of the following: a) Pt has experienced inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with MTX, cyclosporine, or acitretin, OR b) pharmacologic treatment with MTX, cyclosporine, or acitretin is contraindicated, OR c) Pt has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of BSA or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | For hidradenitis suppurativa (new starts only): Pt has severe, refractory disease. For uveitis (new starts only): Inadequate treatment response or intolerance or has a contraindication to a trial of immunosuppressive therapy for uveitis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | REPATHA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | REPATHA, REPATHA PUSHTRONEX SYSTEM, REPATHA SURECLICK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RETEVMO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | RETEVMO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | Recurrent rearranged during transfection (RET)-rearrangement positive non-small cell lung cancer (NSCLC), brain metastases from RET fusion-positive NSCLC, Langerhans Cell Histiocytosis with a RET gene fusion, symptomatic or relapsed/refractory Erdheim-Chester Disease with a RET gene fusion, symptomatic or relapsed/refractory Rosai-Dorfman Disease with a RET gene fusion, occult primary cancer with RET gene fusion, solid tumors with RET-gene fusion for recurrent disease                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC), patient must meet all of the following: 1) The disease is recurrent, advanced or metastatic, AND 2) The tumor is rearranged during transfection (RET) fusion-positive or RET rearrangement positive. For solid tumors, patient must meet all of the following: 1) The disease is recurrent, persistent, progressive, unresectable, locally advanced, or metastatic, 2) The patient has progressed on or following prior systemic treatment or has no satisfactory alternative treatment options, AND 3) The tumor is RET fusion-positive. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | REVLIMID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | LENALIDOMIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Systemic light chain amyloidosis, classical Hodgkin lymphoma, myelodysplastic syndrome without the 5q deletion cytogenetic abnormality, myelofibrosis-associated anemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, myeloproliferative neoplasms, Kaposi Sarcoma, Langerhans cell histiocytosis, Rosai-Dorfman disease, peripheral T-Cell lymphomas not otherwise specified, angioimmunoblastic T-cell lymphoma (AITL), enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, primary central nervous system (CNS) lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), human immunodeficiency virus (HIV)-related B-cell lymphomas, monomorphic post-transplant lymphoproliferative disorder, diffuse large B-cell lymphoma, multicentric Castlemans disease, high-grade B-cell lymphomas, histologic transformation of indolent lymphoma to diffuse large B-cell lymphoma |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For myelodysplastic syndrome (MDS): patient has lower risk MDS with symptomatic anemia per the Revised International Prognostic Scoring System (IPSS-R), International Prognostic Scoring System (IPSS), or World Health organization (WHO) classification-based Prognostic Scoring System (WPSS).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prior Authorization Group</b>    | REVUFORJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | REVUFORJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | REZLIDHIA                    |
| <b>Drug Names</b>                   | REZLIDHIA                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | REZUROCK                     |
| <b>Drug Names</b>                   | REZUROCK                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | 12 years of age or older     |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RINVOQ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | RINVOQ, RINVOQ LQ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For active psoriatic arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active ulcerative colitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active Crohn's disease (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumab-aacf]). For atopic dermatitis (new starts only): 1) Patient has refractory, moderate to severe disease, AND 2) Patient has had an inadequate response to treatment with at least one other systemic drug product, including biologics, or use of these therapies are inadvisable. For atopic dermatitis (continuation of therapy): Patient achieved or maintained positive clinical response. For active ankylosing spondylitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For non-radiographic axial spondyloarthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor. |
| <b>Age Restrictions</b>             | Atopic dermatitis: 12 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Atopic dermatitis (initial): 4 months, All others: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | For active polyarticular juvenile idiopathic arthritis (new starts only): patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                         |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ROMVIMZA                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | ROMVIMZA                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                       |
| <b>Prior Authorization Group</b>    | ROZLYTREK                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ROZLYTREK                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | Recurrent ROS1-positive non-small cell lung cancer (NSCLC), Non-metastatic neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors, first-line treatment of NTRK gene fusion-positive solid tumors, ROS1-gene fusion-positive cutaneous melanoma |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors: the disease is without a known acquired resistance mutation. For ROS1-positive non-small cell lung cancer: the patient has recurrent, advanced, or metastatic disease.          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                       |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RUBRACA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | RUBRACA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Uterine leiomyosarcoma, pancreatic adenocarcinoma, advanced (stage II-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For metastatic castration-resistant prostate cancer with a deleterious breast cancer susceptibility gene (BRCA) mutation (germline and/or somatic): 1) patient has been treated with androgen receptor-directed therapy, AND 2) patient has been treated with a taxane-based chemotherapy or the patient is not fit for chemotherapy, AND 3) the requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy. For maintenance treatment of BRCA mutated ovarian, fallopian tube, primary peritoneal cancer: 1) the patient has advanced (stage II-IV) disease and is in complete or partial response to primary therapy, OR 2) the patient has recurrent disease and is in complete or partial response to platinum-based chemotherapy. For uterine leiomyosarcoma: 1) the requested drug is used as second-line therapy, AND 2) the patient has BRCA-altered disease. For pancreatic adenocarcinoma: 1) the patient has metastatic disease, AND 2) the patient has somatic or germline BRCA or PALB-2 mutations. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | RYBELSUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | RYBELSUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | RYDAPT                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | RYDAPT                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Relapsed or refractory acute myeloid leukemia (AML), myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FGFR1 or FLT3 rearrangements, post-induction therapy for AML, re-induction in residual disease for AML                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For acute myeloid leukemia (AML): AML is FMS-like tyrosine kinase 3 (FLT3) mutation-positive. For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and Fibroblast growth factor receptor type 1 (FGFR1) or FLT3 rearrangements: the disease is in chronic or blast phase.                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | SAPROPTERIN                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | JAVYGTOR, SAPROPTERIN DIHYDROCHLORI                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For phenylketonuria (PKU): For patients who have not yet received a therapeutic trial of the requested drug, the patient's pretreatment (including before dietary management) phenylalanine level is greater than 6 mg/dL (360 micromol/L). For patients who completed a therapeutic trial of the requested drug, the patient must have experienced improvement (e.g., reduction in blood phenylalanine levels, improvement in neuropsychiatric symptoms). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Initial: 2 months, All others: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SCEMBLIX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | SCEMBLIX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in chronic phase or blast phase.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML) in the chronic phase: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) Patient meets one of the following: A) Patient has newly diagnosed CML and has resistance or intolerance to imatinib, dasatinib, or nilotinib OR B) Patient has previously treated CML AND at least one of the prior treatments was imatinib, dasatinib, or nilotinib OR C) Patient is positive for the T315I mutation, AND 3) Patient is negative for the following mutations: A337T, P465S. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | SIGNIFOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | SIGNIFOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an endocrinologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | SILDENAFIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | SILDENAFIL CITRATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) If the request is for an adult, pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units.                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SIRTURO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | SIRTURO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with an infectious disease specialist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | SKYRIZI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | SKYRIZI, SKYRIZI PEN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SOMATULINE DEPOT                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | LANREOTIDE ACETATE, SOMATULINE DEPOT                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | Tumor control of neuroendocrine tumors (NETs) (including tumors of the lung, thymus, well-differentiated grade 3 NETs not of gastroenteropancreatic origin with favorable biology, and pheochromocytoma/paraganglioma)                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range, AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly, continuation of therapy: Patient's IGF-1 level has decreased or normalized since initiation of therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | SOMAVERT                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | SOMAVERT                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For acromegaly, initial: 1) Patient has a high pretreatment insulin-like growth factor-1 (IGF-1) level for age and/or gender based on the laboratory reference range, AND 2) Patient had an inadequate or partial response to surgery or radiotherapy OR there is a clinical reason for why the patient has not had surgery or radiotherapy. For acromegaly, continuation of therapy: Patient's IGF-1 level has decreased or normalized since initiation of therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SOTYKTU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | SOTYKTU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SPRYCEL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | DASATINIB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | Gastrointestinal stromal tumor (GIST), metastatic and/or widespread chondrosarcoma, recurrent chordoma, T-cell acute lymphoblastic leukemia (ALL), and Philadelphia (Ph)-like B-ALL, myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase, cutaneous melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia (Ph) chromosome or BCR-ABL gene AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I/A, F317L/V/I/C, and V299L. For acute lymphoblastic leukemia (ALL), the patient has a diagnosis of one of the following: 1) Philadelphia chromosome positive ALL, including patients who have received a hematopoietic stem cell transplant: Diagnosis that has been confirmed by detection of the Ph chromosome or BCR-ABL gene AND if patient experienced resistance to an alternative tyrosine kinase inhibitor, patient is negative for all of the following mutations: T315I/A, F317L/V/I/C, and V299L OR 2) Ph-like B-ALL with ABL-class kinase fusion OR 3) Relapsed or refractory T-cell ALL with ABL-class translocation. For gastrointestinal stromal tumor (GIST): 1) Patient meets all of the following: A) Disease is residual, unresectable, recurrent/progressive, or metastatic/tumor rupture, B) Patient has received prior therapy with avapritinib AND C) Patient is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations. For cutaneous melanoma: 1) Disease is metastatic or unresectable, 2) Disease is positive for c-KIT activating mutations AND 3) Requested drug will be used as subsequent therapy AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | STELARA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | STELARA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | STIVARGA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | STIVARGA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Off-label Uses</b>               | Osteosarcoma, glioblastoma, angiosarcoma, retroperitoneal/intra-abdominal soft tissue sarcoma, rhabdomyosarcoma, soft tissue sarcomas of the extremities, body wall, head and neck, appendiceal adenocarcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For colorectal cancer: 1) The disease is advanced or metastatic, AND 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to Lonsurf (trifluridine/tipiracil).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SUTENT                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | SUNITINIB MALATE                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Thyroid carcinoma (follicular, medullary, papillary, and oncocytic), soft tissue sarcoma (angiosarcoma, solitary fibrous tumor, and alveolar soft part sarcoma subtypes), recurrent chordoma, thymic carcinoma, lymphoid and/or myeloid neoplasms with eosinophilia and FLT3 rearrangement in chronic or blast phase, pheochromocytoma, paraganglioma, well differentiated grade 3 neuroendocrine tumors |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For renal cell carcinoma (RCC): 1) The disease is relapsed, advanced, or stage IV OR 2) the requested drug is being used as adjuvant treatment for patients that are at high risk of recurrent RCC following nephrectomy.                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | SYMDEKO                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | SYMDEKO                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For cystic fibrosis: The requested medication will not be used in combination with other medications containing ivacaftor.                                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | 6 years of age or older                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | SYMPAZAN                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | SYMPAZAN                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Seizures associated with Dravet syndrome                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | Seizures associated with Lennox-Gastaut syndrome (LGS): 2 years of age or older                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | SYNAREL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | SYNAREL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For central precocious puberty (CPP): Patients not currently receiving therapy must meet all of the following criteria: 1) Diagnosis of CPP was confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level of a third generation luteinizing hormone (LH) assay, AND 2) Assessment of bone age versus chronological age supports the diagnosis of CPP, AND 3) The onset of secondary sexual characteristics occurred prior to 8 years of age for female patients OR prior to 9 years of age for male patients. For management of endometriosis: Patient has not already received greater than or equal to 6 months of treatment with the requested drug. |
| <b>Age Restrictions</b>             | CPP: Patient must be less than 12 years of age if female and less than 13 years of age if male, Endometriosis: 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prior Authorization Group</b>    | TABRECTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | TABRECTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level mesenchymal-epithelial transition (MET) amplification, central nervous system (CNS) brain metastases from MET exon-14 mutated NSCLC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC): Tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TADALAFIL (BPH)                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | TADALAFIL                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | Erectile Dysfunction.                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For benign prostatic hyperplasia (BPH): the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to both of the following: 1) alpha blocker, 2) 5-alpha reductase inhibitor (5-ARI).                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | 26 weeks                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | TADALAFIL (PAH)                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | ALYQ, TADALAFIL                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For PAH new starts only: 1) Pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) Pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TAFINLAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | TAFINLAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Langerhans cell histiocytosis, Erdheim-Chester disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For melanoma: 1) The tumor is positive for a BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) The requested drug will be used as a single agent or in combination with trametinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, b) adjuvant systemic therapy. For non-small cell lung cancer: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested drug will be used as a single agent or in combination with trametinib. For papillary, follicular, and oncocyctic thyroid carcinoma: 1) The tumor is BRAF V600E-positive, AND 2) The disease is not amenable to radioactive iodine (RAI) therapy, AND 3) the requested drug will be used in combination with trametinib. For Langerhans Cell Histiocytosis and Erdheim-Chester Disease: The disease is positive for a BRAF V600E mutation. For solid tumors: 1) The tumor is positive for a BRAF V600E mutation, AND 2) The requested drug will be used in combination with trametinib. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | TAGRISSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | TAGRISSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Sensitizing epidermal growth factor receptor (EGFR) mutation-positive recurrent non-small cell lung cancer (NSCLC), brain metastases from sensitizing EGFR mutation-positive NSCLC, leptomeningeal metastases from EGFR mutation-positive NSCLC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC), the requested drug is used in any of the following settings: 1) The patient meets both of the following: a) patient has unresectable, metastatic, advanced, or recurrent NSCLC (including brain and/or leptomeningeal metastases from NSCLC) and b) patient has a sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease, OR 2) The patient meets both of the following: a) request is for adjuvant treatment of NSCLC following tumor resection and b) patient has EGFR mutation-positive disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TALZENNA                                                                                                                                                                                       |
| <b>Drug Names</b>                   | TALZENNA                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                              |
| <b>Off-label Uses</b>               | Recurrent germline breast cancer susceptibility gene (BRCA)-mutated breast cancer                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | TARGRETIN TOPICAL                                                                                                                                                                              |
| <b>Drug Names</b>                   | BEXAROTENE                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                              |
| <b>Off-label Uses</b>               | Mycosis fungoides (MF)/Sezary syndrome (SS), chronic or smoldering adult T-cell leukemia/lymphoma (ATLL), primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                              |
| <b>Required Medical Information</b> | -                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TASIGNA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | NILOTINIB HYDROCHLORIDE, TASIGNA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumor (GIST), myeloid and/or lymphoid neoplasms with eosinophilia and ABL1 rearrangement in the chronic phase or blast phase, pigmented villonodular synovitis/tenosynovial giant cell tumor, cutaneous melanoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For chronic myeloid leukemia (CML), including patients newly diagnosed with CML and patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If patient experienced resistance to an alternative tyrosine kinase inhibitor for CML, patient is negative for T315I, Y253H, E255K/V, and F359V/C/I mutations. For acute lymphoblastic leukemia (ALL), including patients who have received a hematopoietic stem cell transplant: 1) Diagnosis was confirmed by detection of the Philadelphia chromosome or BCR-ABL gene, AND 2) If the patient has experienced resistance to an alternative tyrosine kinase inhibitor for ALL, patient is negative for T315I, Y253H, E255K/V, F359V/C/I and G250E mutations. For gastrointestinal stromal tumor (GIST): 1) Disease is residual, unresectable, recurrent/progressive, or metastatic/tumor rupture, AND 2) Disease has progressed on at least 2 Food and Drug Administration (FDA)-approved therapies (e.g. imatinib, sunitinib, regorafenib, ripretinib). For cutaneous melanoma: 1) Disease is metastatic or unresectable, AND 2) Disease is positive for c-KIT activating mutations, AND 3) Requested drug will be used as subsequent therapy, AND 4) Patient has had disease progression, intolerance, or risk of progression with BRAF-targeted therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | TAVNEOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | TAVNEOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For continuation of treatment for severe anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis: the patient has experienced benefit from therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TAZAROTENE                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | TAZAROTENE, TAZORAC                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For plaque psoriasis, the patient meets the following criteria: 1) the patient has less than or equal to 20 percent of affected body surface area (BSA), AND 2) the patient experienced an inadequate treatment response or intolerance to at least one topical corticosteroid OR has a contraindication that would prohibit a trial of topical corticosteroids. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | TAZVERIK                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | TAZVERIK                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | Epithelioid sarcoma: 16 years of age or older, Follicular lymphoma: 18 years of age or older                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TECENTRIQ                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | TECENTRIQ                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Single agent maintenance for extensive small cell lung cancer following combination treatment with etoposide and carboplatin, subsequent therapy for peritoneal mesothelioma, pericardial mesothelioma, and tunica vaginalis testis mesothelioma, urothelial carcinoma, stage IIIB non-small cell lung cancer (NSCLC), persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC). |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced, or metastatic disease OR 2) the patient has stage II to IIIB disease AND the requested drug will be used as adjuvant treatment following resection and adjuvant chemotherapy. For hepatocellular carcinoma, the requested drug will be used as initial treatment in combination with bevacizumab.                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | TECENTRIQ HYBREZA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Drug Names</b>                   | TECENTRIQ HYBREZA                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC), stage IIIB non-small cell lung cancer (NSCLC), subsequent therapy for peritoneal mesothelioma, pericardial mesothelioma, and tunica vaginalis testis mesothelioma.                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced or metastatic disease OR 2) the patient has stage II to IIIB disease AND the requested drug will be used as adjuvant treatment following resection and adjuvant chemotherapy. For hepatocellular carcinoma, the requested drug will be used as initial treatment in combination with bevacizumab.                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TEMAZEPAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | TEMAZEPAM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For short-term treatment of insomnia: 1) The prescriber must acknowledge that the benefit of therapy with this prescribed medication outweighs the potential risks for the patient. (Note: The use of this medication is potentially inappropriate in older adults, meaning it is best avoided, prescribed at reduced dosage, or used with caution or carefully monitored.) AND 2) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to doxepin (3 mg or 6 mg). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | This Prior Authorization only applies to patients 65 years of age or older.                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | TEPMETKO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | TEPMETKO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent non-small cell lung cancer (NSCLC), NSCLC with high level mesenchymal-epithelial transition (MET) amplification, central nervous system (CNS) cancer including brain metastases and leptomeningeal metastases from MET exon-14 mutated NSCLC                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC): Tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutation.                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | TERBINAFINE TABS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | TERBINAFINE HCL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For the treatment of onychomycosis due to dermatophytes (tinea unguium), patient meets ALL of the following: 1) the patient will use the requested drug orally., AND 2) the requested drug is being prescribed for non-continuous use.                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | Prior authorization applies to greater than cumulative 90 days of therapy per year.                                                                                                                                                                                                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TERIPARATIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | TERIPARATIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | <p>For postmenopausal osteoporosis: patient has ONE of the following: 1) history of fragility fracture, OR 2) pre-treatment T-score of less than or equal to -2.5 or pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment Fracture Risk Assessment Tool (FRAX) fracture probability AND patient has ANY of the following: a) indicators for higher fracture risk (e.g., advanced age, frailty, glucocorticoid therapy, very low T-scores, or increased fall risk), OR b) patient has failed prior treatment with or is intolerant to a previous injectable osteoporosis therapy OR c) patient has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate. For primary or hypogonadal osteoporosis in men: patient has ONE of the following: 1) history of osteoporotic vertebral or hip fracture, OR 2) pre-treatment T-score of less than or equal to -2.5, or pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment FRAX fracture probability AND patient has ANY of the following: a) patient has failed prior treatment with or is intolerant to a previous injectable osteoporosis therapy, OR b) patient has had an oral bisphosphonate trial of at least 1-year duration or there is a clinical reason to avoid treatment with an oral bisphosphonate. For glucocorticoid-induced osteoporosis: patient has had an oral bisphosphonate trial of at least 1-year duration unless patient has a contraindication or intolerance to an oral bisphosphonate, AND patient meets ANY of the following: 1) patient has a history of fragility fracture, OR 2) pre-treatment T-score of less than or equal to -2.5, OR 3) pre-treatment T-score greater than -2.5 and less than -1 with a high pre-treatment FRAX fracture probability.</p> |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Initial: 24 months, Continuation: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | Continuation of therapy: If the patient has received greater than or equal to 24 months of therapy with any parathyroid hormone analog: 1) The patient remains at or has returned to having a high risk for fracture, AND 2) The benefit of therapy with this prescribed medication outweighs the potential risks for this patient. Patient has high FRAX fracture probability if the 10-year probability is either greater than or equal to 20 percent for any major osteoporotic fracture or greater than or equal to 3 percent for hip fracture. If glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) per day, the estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TESTOSTERONE CYPIONATE INJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Gender Dysphoria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed decision to engage in hormone therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | TESTOSTERONE ENANTHATE INJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | TESTOSTERONE ENANTHATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Gender Dysphoria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed decision to engage in hormone therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TETRABENAZINE                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | TETRABENAZINE                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                |
| <b>Off-label Uses</b>               | Tic disorders, tardive dyskinesia, hemiballismus, chorea not associated with Huntington's disease.                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For treatment of tardive dyskinesia and treatment of chorea associated with Huntington's disease: The patient has experienced an inadequate treatment response or intolerable adverse event to deutetrabenazine. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | THALOMID                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | THALOMID                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                |
| <b>Off-label Uses</b>               | Myelofibrosis-associated anemia, acquired immunodeficiency syndrome (AIDS)-related aphthous stomatitis, Kaposi sarcoma, multicentric Castleman's disease, Rosai-Dorfman disease, Langerhans cell histiocytosis   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TIBSOVO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | TIBSOVO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Conventional (grades 1-3) or dedifferentiated chondrosarcoma, central nervous system (CNS) cancers (astrocytoma, oligodendroglioma)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | Patient has disease with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. For acute myeloid leukemia (AML): 1) patient has newly-diagnosed AML and meets one of the following: a) 75 years of age or older, b) patient has comorbidities that preclude use of intensive induction chemotherapy, OR 2) the requested drug will be used as post-induction therapy following response to induction therapy with the requested drug, OR 3) patient has relapsed or refractory AML. For locally advanced, unresectable, resected gross residual, or metastatic cholangiocarcinoma: the requested drug will be used as subsequent treatment for progression on or after systemic treatment. For CNS cancers: 1) disease is recurrent or progressive, AND 2) patient has oligodendroglioma or astrocytoma. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | TOBI INHALER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | TOBI PODHALER                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | Non-cystic fibrosis bronchiectasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For cystic fibrosis and non-cystic fibrosis bronchiectasis: 1) Pseudomonas aeruginosa is present in the patient's airway cultures, OR 2) The patient has a history of Pseudomonas aeruginosa infection or colonization in the airways.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TOBRAMYCIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | TOBRAMYCIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Non-cystic fibrosis bronchiectasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For cystic fibrosis and non-cystic fibrosis bronchiectasis: 1) Pseudomonas aeruginosa is present in the patient's airway cultures, OR 2) The patient has a history of Pseudomonas aeruginosa infection or colonization in the airways.                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | TOPICAL LIDOCAINE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | GLYDO, LIDOCAINE, LIDOCAINE HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | 1) The requested drug is being used for topical anesthesia, AND 2) If the requested drug will be used as part of a compounded product, then all the active ingredients in the compounded product are Food and Drug Administration (FDA) approved for topical use.                                                                                                                                                                                                                                          |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | 3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | TOPICAL TACROLIMUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | TACROLIMUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | Psoriasis on the face, genitals, or skin folds.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Required Medical Information</b> | For moderate to severe atopic dermatitis (eczema): the patient meets either of the following criteria: 1) the disease affects sensitive skin areas (e.g., face, genitals, or skin folds), OR 2) the patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one first line therapy agent (e.g., medium or higher potency topical corticosteroid). For all indications: the requested drug is being prescribed for short-term or non-continuous chronic use. |
| <b>Age Restrictions</b>             | Tacrolimus 0.03% 2 years of age or older, Tacrolimus 0.1% 16 years of age or older.                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TOPICAL TESTOSTERONES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | TESTOSTERONE, TESTOSTERONE PUMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | Gender Dysphoria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | For primary hypogonadism or hypogonadotropic hypogonadism, initial therapy: The patient has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For primary hypogonadism or hypogonadotropic hypogonadism, continuation of therapy: The patient had a confirmed low morning serum total testosterone concentration based on the reference laboratory range or current practice guidelines before starting testosterone therapy [Note: Safety and efficacy of testosterone products in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]. For gender dysphoria: The patient is able to make an informed decision to engage in hormone therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | TOPICAL TRETINOIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | TRETINOIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prior Authorization Group</b>    | TOREMIFENE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | TOREMIFENE CITRATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | Congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TRAZIMERA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | TRAZIMERA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, recurrent or advanced unresectable HER2-positive breast cancer, leptomeningeal metastases from HER2-positive breast cancer, brain metastases from HER2-positive breast cancer, HER2-positive esophageal and esophagogastric junction adenocarcinoma, HER2-positive advanced, recurrent, or metastatic uterine serous carcinoma, HER2-amplified and RAS and BRAF wild-type colorectal cancer (including appendiceal adenocarcinoma), HER2-positive recurrent salivary gland tumor, HER2-positive unresectable or metastatic hepatobiliary carcinoma (gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma), HER2 overexpression positive locally advanced, unresectable, or recurrent gastric adenocarcinoma, HER2-positive endometrial cancer. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For colorectal cancer (including appendiceal adenocarcinoma): 1) the disease is HER2-amplified and RAS and BRAF wild-type and 2) the requested drug is used in combination with pertuzumab, tucatinib or lapatinib and 3) the patient has not had previous treatment with a HER2 inhibitor. For hepatobiliary carcinoma: 1) the disease is HER2 positive and 2) the requested drug is used in combination with pertuzumab. For endometrial cancer: 1) the requested drug is being used in combination with carboplatin and paclitaxel and 2) continued as a single agent for maintenance therapy.                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TREMFYA - PENDING CMS REVIEW                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Drug Names</b>                   | TREMFYA, TREMFYA INDUCTION PACK FO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, scalp, groin, intertriginous areas) are affected at the time of diagnosis AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prior Authorization Group</b>    | TREPROSTINIL INJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | TREPROSTINIL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For pulmonary arterial hypertension (World Health Organization [WHO] Group 1): PAH was confirmed by right heart catheterization. For new starts only: 1) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, AND 2) pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg, AND 3) pretreatment pulmonary vascular resistance is greater than or equal to 3 Wood units.                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

|                                     |                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TRIENTINE                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | TRIENTINE HYDROCHLORIDE                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | TRIKAFTA                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | TRIKAFTA                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For cystic fibrosis: The requested medication will not be used in combination with other medications containing ivacaftor.                                                                                                                                                                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Prior Authorization Group</b>    | TRINTELLIX                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | TRINTELLIX                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                       |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For major depressive disorder (MDD): The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to ONE of the following generic products: serotonin and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), mirtazapine, bupropion. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                  |

|                                     |                                                                           |
|-------------------------------------|---------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TRULICITY                                                                 |
| <b>Drug Names</b>                   | TRULICITY                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                              |
| <b>Off-label Uses</b>               | -                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                         |
| <b>Required Medical Information</b> | -                                                                         |
| <b>Age Restrictions</b>             | For glycemic control in type 2 diabetes mellitus:10 years of age or older |
| <b>Prescriber Restrictions</b>      | -                                                                         |
| <b>Coverage Duration</b>            | Plan Year                                                                 |
| <b>Other Criteria</b>               | -                                                                         |

|                                     |                              |
|-------------------------------------|------------------------------|
| <b>Prior Authorization Group</b>    | TRUQAP                       |
| <b>Drug Names</b>                   | TRUQAP                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications |
| <b>Off-label Uses</b>               | -                            |
| <b>Exclusion Criteria</b>           | -                            |
| <b>Required Medical Information</b> | -                            |
| <b>Age Restrictions</b>             | -                            |
| <b>Prescriber Restrictions</b>      | -                            |
| <b>Coverage Duration</b>            | Plan Year                    |
| <b>Other Criteria</b>               | -                            |

**Prior Authorization Group****Drug Names****PA Indication Indicator****Off-label Uses**

TRUXIMA

TRUXIMA

All FDA-approved Indications, Some Medically-accepted Indications

Non-Hodgkin's lymphoma subtypes [small lymphocytic lymphoma (SLL), mantle cell lymphoma, marginal zone lymphomas (nodal, splenic, extranodal marginal zone lymphoma), Burkitt lymphoma, high-grade B-cell lymphoma, histological transformation from indolent lymphomas to diffuse large B-cell lymphoma, histological transformation chronic lymphocytic leukemia (CLL)/SLL to diffuse large B-cell lymphoma, primary cutaneous B-cell lymphoma, Castleman disease, human immunodeficiency virus (HIV)-related B-cell lymphoma, hairy cell leukemia, post-transplant lymphoproliferative disorder (PTLD), B-cell lymphoblastic lymphoma], refractory immune or idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, chronic graft-versus-host disease (GVHD), Sjogren syndrome, thrombotic thrombocytopenic purpura, refractory myasthenia gravis, Hodgkin's lymphoma (nodular lymphocyte-predominant), primary central nervous system (CNS) lymphoma, leptomeningeal metastases from lymphomas, acute lymphoblastic leukemia, prevention of Epstein-Barr virus (EBV)-related PTLD, multiple sclerosis, immune checkpoint inhibitor-related toxicities, Rosai-Dorfman disease, pemphigus vulgaris, pediatric aggressive mature B-cell lymphomas (including Burkitt-like lymphoma, primary mediastinal large B-cell lymphoma), and pediatric mature B-cell acute leukemia

**Exclusion Criteria**

-

**Required Medical Information**

For moderately to severely active rheumatoid arthritis (new starts only): 1) patient meets ANY of the following: a) requested drug will be used in combination with methotrexate (MTX) OR b) patient has intolerance or contraindication to MTX, AND 2) patient meets ANY of the following: a) inadequate response, intolerance, or contraindication to MTX OR b) inadequate response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD. Hematologic malignancies must be CD20-positive. For multiple sclerosis: 1) patient has a diagnosis of relapsing remitting multiple sclerosis, AND 2) patient has had an inadequate response to two or more disease-modifying drugs indicated for multiple sclerosis despite adequate duration of treatment.

**Age Restrictions**

-

**Prescriber Restrictions**

-

**Coverage Duration**

Immune checkpoint inhibitor-related toxicities: 3 months, All other: Plan Year

**Other Criteria**

-

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | TUKYSA                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | TUKYSA                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer                                                                                                                                                                                                                                                                                                                                         |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For colorectal cancer (including appendiceal adenocarcinoma): 1) the patient has advanced, unresectable, or metastatic disease, AND 2) the patient has human epidermal growth factor receptor 2 (HER2)-positive disease, AND 3) the patient has RAS wild-type disease, AND 4) the requested drug will be used in combination with trastuzumab, AND 5) the patient has not previously been treated with a HER2 inhibitor. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | TURALIO                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | TURALIO                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For Langerhans cell histiocytosis: 1) disease has colony stimulating factor 1 receptor (CSF1R) mutation. For Erdheim-Chester disease and Rosai-Dorfman disease: 1) disease has CSF1R mutation AND patient has any of the following: a) symptomatic disease OR b) relapsed/refractory disease.                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | TYENNE                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | TYENNE                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Castleman's disease, systemic sclerosis-associated interstitial lung disease                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): 1) Patient has experienced an inadequate treatment response, intolerance or contraindication to methotrexate (MTX) OR 2) Patient has experienced an inadequate response or intolerance to a prior biologic disease-modifying antirheumatic drug (DMARD) or a targeted synthetic DMARD.                                                         |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | UBRELVY                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | UBRELVY                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For acute treatment of migraine: The patient has experienced an inadequate treatment response, intolerance, or the patient has a contraindication to at least one triptan 5-HT1 receptor agonist.                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | UCERIS                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | BUDESONIDE ER                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For the induction of remission of active, mild to moderate ulcerative colitis: patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one 5-aminosalicylic acid (5-ASA) therapy.                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | 2 months                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | VALCHLOR                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | VALCHLOR                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Chronic or smoldering adult T-cell leukemia/lymphoma (ATLL), Stage 2 or higher mycosis fungoides (MF)/Sezary syndrome (SS), primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, CD30-positive lymphomatoid papulosis (LyP), unifocal Langerhans cell histiocytosis (LCH) with isolated skin disease |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VANFLYTA                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | VANFLYTA                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Relapsed or refractory acute myeloid leukemia                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For acute myeloid leukemia (AML): AML is FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD)-positive.                                                                                                                                                                                                                              |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | VELCADE                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | BORTEZOMIB                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Systemic light chain amyloidosis, Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, multicentric Castleman's disease, adult T-cell leukemia/lymphoma, acute lymphoblastic leukemia, Kaposi's sarcoma, pediatric Classic Hodgkin lymphoma, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | VELSIPITY                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | VELSIPITY                                                                                                                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VENCLEXTA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | VENCLEXTA, VENCLEXTA STARTING PACK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Off-label Uses</b>               | Mantle cell lymphoma, blastic plasmacytoid dendritic cell neoplasm (BPDCN), multiple myeloma, relapsed or refractory acute myeloid leukemia (AML), Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, relapsed or refractory systemic light chain amyloidosis with translocation t(11:14), accelerated or blast phase myeloproliferative neoplasms, B-cell acute lymphoblastic leukemia/T-cell acute lymphoblastic leukemia (B-ALL/T-ALL), hairy cell leukemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | For acute myeloid leukemia (AML): 1) patient has newly-diagnosed AML and meets one of the following: a) 75 years of age or older, b) patient has comorbidities that preclude use of intensive induction chemotherapy, OR 2) patient has poor/adverse risk disease and is a candidate for intensive induction therapy, OR 3) patient has relapsed or refractory AML. For blastic plasmacytoid dendritic cell neoplasm (BPDCN): 1) patient has systemic disease being treated with palliative intent, OR 2) patient has relapsed or refractory disease. For multiple myeloma: 1) the disease is relapsed or progressive, AND 2) the requested drug will be used in combination with dexamethasone, AND 3) patient has t(11:14) translocation. For Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: 1) patient has previously treated disease that did not respond to primary therapy, OR 2) patient has progressive or relapsed disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prior Authorization Group</b>    | VEOZAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | VEOZAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VERQUVO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | VERQUVO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For symptomatic chronic heart failure: the patient has a left ventricular ejection fraction (LVEF) less than 45 percent. For initial therapy, the patient meets ANY of the following: 1) hospitalization for heart failure within the past 6 months OR 2) use of outpatient intravenous diuretics for heart failure within the past 3 months.                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | VERSACLOZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | VERSACLOZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For the treatment of a severely ill patient with schizophrenia who failed to respond adequately to standard antipsychotic treatment (i.e., treatment-resistant schizophrenia): 1) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following generic products: aripiprazole, asenapine, lurasidone, olanzapine, quetiapine, risperidone, ziprasidone, AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to one of the following brand products: Caplyta, Lybalvi, Rexulti, Secuado, Vraylar. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VERZENIO                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | VERZENIO                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | Recurrent hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in combination with fulvestrant or an aromatase inhibitor, or as a single agent if progression on prior endocrine therapy and prior chemotherapy in the metastatic setting. Endometrial cancer, in combination with letrozole for estrogen receptor positive tumor. |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | VIGABATRIN                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | VIGABATRIN, VIGADRONE, VIGPODER                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For complex partial seizures (i.e., focal impaired awareness seizures): patient has experienced an inadequate treatment response to at least two antiepileptic drugs for complex partial seizures (i.e., focal impaired awareness seizures).                                                                                                                                         |
| <b>Age Restrictions</b>             | Infantile Spasms: 1 month to 2 years of age. Complex partial seizures (i.e., focal impaired awareness seizures): 2 years of age or older                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | VIGAFYDE                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | VIGAFYDE                                                                                                                                                                                                                                                                                                                                                                             |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Age Restrictions</b>             | Infantile Spasms: 1 month to 2 years of age                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                     |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VITRAKVI                                                                                                                                                                                            |
| <b>Drug Names</b>                   | VITRAKVI                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                   |
| <b>Off-label Uses</b>               | Non-metastatic neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors, first-line treatment of NTRK gene fusion-positive solid tumors.                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For all neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors, the disease is without a known acquired resistance mutation.                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | VIZIMPRO                                                                                                                                                                                            |
| <b>Drug Names</b>                   | VIZIMPRO                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                   |
| <b>Off-label Uses</b>               | Recurrent non-small cell lung cancer (NSCLC)                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the disease is recurrent, advanced, or metastatic, and 2) the patient has sensitizing epidermal growth factor receptor (EGFR) mutation-positive disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | VONJO                                                                                                                                                                                               |
| <b>Drug Names</b>                   | VONJO                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                   |
| <b>Off-label Uses</b>               | Accelerated or blast phase myeloproliferative neoplasms                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                   |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VORANIGO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | VORANIGO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | VORICONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | VORICONAZOLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | The patient will use the requested drug orally or intravenously.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | VOSEVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | VOSEVI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | Decompensated cirrhosis/moderate or severe hepatic impairment (Child Turcotte Pugh class B or C)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For hepatitis C: Infection confirmed by presence of HCV RNA in the serum prior to starting treatment. Planned treatment regimen, genotype, prior treatment history, presence or absence of cirrhosis (compensated or decompensated [Child Turcotte Pugh class B or C]), presence or absence of HIV coinfection, presence or absence of resistance-associated substitutions where applicable, transplantation status if applicable. Coverage conditions and specific durations of approval will be based on current American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD-IDSA) treatment guidelines. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Criteria will be applied consistent with current AASLD-IDSA guidance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | VOTRIENT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Drug Names</b>                   | PAZOPANIB HYDROCHLORIDE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Off-label Uses</b>               | Thyroid carcinoma (follicular, papillary, oncocytic, or medullary), uterine sarcoma, chondrosarcoma, gastrointestinal stromal tumor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For renal cell carcinoma: 1) the disease is advanced, relapsed, or stage IV, OR 2) the requested drug will be used for von Hippel-Lindau (VHL)-associated renal cell carcinoma. For gastrointestinal stromal tumor (GIST): 1) the disease is residual, unresectable, recurrent, or metastatic/tumor rupture AND 2) the patient meets one of the following: a) the disease has progressed after at least two FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib), b) the disease is succinate dehydrogenase (SDH)-deficient GIST. For soft tissue sarcoma (STS): the patient does not have an adipocytic soft tissue sarcoma. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | VOWST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | VOWST                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | For the prevention of recurrence of Clostridioides difficile infection (CDI): 1) The diagnosis of CDI has been confirmed by a positive stool test for C. difficile toxin, AND 2) The requested drug will be administered at least 48 hours after the last dose of antibiotics used for the treatment of recurrent CDI.                                                                                                                                                                                                                                                                                                                               |
| <b>Age Restrictions</b>             | 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | 1 month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prior Authorization Group</b>    | WELIREG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | WELIREG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XALKORI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | XALKORI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Off-label Uses</b>               | Recurrent non-small cell lung cancer (NSCLC), NSCLC with high-level MET amplification or MET exon 14 skipping mutation, symptomatic or relapsed/refractory anaplastic lymphoma kinase (ALK)-fusion positive Erdheim-Chester Disease, symptomatic or relapsed/refractory (ALK)-fusion positive Rosai-Dorfman Disease, (ALK)-fusion positive Langerhans Cell Histiocytosis, metastatic or unresectable ROS1 gene fusion positive cutaneous melanoma.                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC), the requested drug is used in any of the following settings: 1) the patient has recurrent, advanced or metastatic anaplastic lymphoma kinase (ALK)-positive NSCLC AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib), OR 3) the patient has recurrent, advanced or metastatic ROS-1 positive NSCLC, OR 4) the patient has NSCLC with high-level MET amplification or MET exon 14 skipping mutation. For inflammatory myofibroblastic tumor (IMT), the disease is ALK-positive. For anaplastic large cell lymphoma (ALCL): 1) the disease is relapsed or refractory, AND 2) the disease is ALK-positive. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prior Authorization Group</b>    | XDEMYY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | XDEMYY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XELJANZ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | XELJANZ, XELJANZ XR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For moderately to severely active rheumatoid arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For active psoriatic arthritis (new starts only): 1) Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one TNF inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]) AND 2) the requested drug is used in combination with a nonbiologic DMARD. For active ankylosing spondylitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). For moderately to severely active ulcerative colitis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Humira [adalimumab], Idacio [adalimumab-aacf]). For active polyarticular course juvenile idiopathic arthritis (new starts only): Patient has experienced an inadequate treatment response, intolerance, or has a contraindication to at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab-aacf, Enbrel [etanercept], Humira [adalimumab], Idacio [adalimumab-aacf]). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prior Authorization Group</b>    | XERMELO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | XERMELO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XGEVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Drug Names</b>                   | XGEVA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For hypercalcemia of malignancy: condition is refractory to intravenous (IV) bisphosphonate therapy or there is a clinical reason to avoid IV bisphosphonate therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prior Authorization Group</b>    | XHANCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Drug Names</b>                   | XHANCE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Age Restrictions</b>             | 18 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prior Authorization Group</b>    | XIFAXAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Drug Names</b>                   | XIFAXAN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Off-label Uses</b>               | Small intestinal bacterial overgrowth syndrome (SIBO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Required Medical Information</b> | For irritable bowel syndrome with diarrhea (IBS-D): 1) The patient has not previously received treatment with the requested drug, OR 2) The patient has previously received treatment with the requested drug, AND a) the patient is experiencing a recurrence of symptoms, AND b) the patient has not already received an initial 14-day course of treatment and two additional 14-day courses of treatment with the requested drug. For small intestinal bacterial overgrowth (SIBO): 1) the patient is experiencing a recurrence after completing a successful course of treatment with the requested drug OR 2) diagnosis has been confirmed by one of the following: a) quantitative culture of upper gut aspirate, b) breath testing (e.g., lactulose hydrogen or glucose hydrogen breath test). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Coverage Duration</b>            | Reduction in risk of overt HE recurrence: 6 months, IBS-D and SIBO: 14 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XOLAIR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | XOLAIR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Required Medical Information</b> | For moderate to severe persistent asthma, initial therapy (tx): 1) Patient (pt) has a positive skin test (or blood test) to at least one perennial aeroallergen, 2) Pt has baseline immunoglobulin E (IgE) level greater than or equal to 30 international units per milliliter (IU/mL), AND 3) Pt has inadequate asthma control despite current tx with both of the following medications: a) Medium-to-high-dose inhaled corticosteroid, AND b) Additional controller (i.e., long acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline) unless pt has an intolerance or contraindication to such therapies. For moderate to severe persistent asthma, continuation of tx (COT): Asthma control has improved on treatment with the requested drug, as demonstrated by a reduction in the frequency and/or severity of symptoms (sx) and exacerbations or a reduction in the daily maintenance oral corticosteroid dose. For chronic spontaneous urticaria (CSU), initial tx: 1) Pt has been evaluated for other causes of urticaria, including bradykinin-related angioedema and interleukin-1 (IL-1)-associated urticarial syndromes (e.g., auto-inflammatory disorders, urticarial vasculitis), 2) Pt has experienced a spontaneous onset of wheals, angioedema, or both, for at least 6 weeks, AND 3) Pt remains symptomatic despite H1 antihistamine treatment. For CSU, COT: Pt has experienced a benefit (e.g., improved sx) since initiation of tx. For chronic rhinosinusitis with nasal polyps (CRSwNP): 1) The requested drug is used as add-on maintenance treatment, AND 2) Pt has experienced inadequate treatment response to Xhance (fluticasone). For IgE-mediated food allergy, initial tx: Pt has baseline IgE level greater than or equal to 30 IU/mL. For IgE-mediated food allergy, COT: Pt has experienced a benefit as evidenced by a decrease in hypersensitivity (e.g., moderate to severe skin, respiratory or gastrointestinal sx) to food allergen. |
| <b>Age Restrictions</b>             | CSU: 12 years of age or older. Asthma: 6 years of age or older. CRSwNP: 18 years of age or older. IgE-mediated food allergy: 1 year of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Coverage Duration</b>            | CSU initial: 6 months, All others: Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

|                                     |                                                                                                                                                                                                                                                  |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XOSPATA                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | XOSPATA                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FLT3 rearrangement                                                                                                                                                           |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and FMS-like tyrosine kinase 3 (FLT3) rearrangement: the disease is in chronic or blast phase.                                                                               |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | XPOVIO                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | XPOVIO, XPOVIO 60 MG TWICE WEEKLY, XPOVIO 80 MG TWICE WEEKLY                                                                                                                                                                                     |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma, Human Immunodeficiency Virus (HIV)-related B-cell lymphoma, high-grade B-cell lymphoma, post-transplant lymphoproliferative disorders                          |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For multiple myeloma: Patient must have been treated with at least one prior therapy.<br>For B-cell lymphomas: Patient must have been treated with at least two lines of systemic therapy.                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | XTANDI                                                                                                                                                                                                                                           |
| <b>Drug Names</b>                   | XTANDI                                                                                                                                                                                                                                           |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For the treatment of castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer: The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | XYREM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Drug Names</b>                   | SODIUM OXYBATE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Required Medical Information</b> | For the treatment of excessive daytime sleepiness in a patient with narcolepsy, initial request: 1) The diagnosis has been confirmed by sleep lab evaluation, AND 2) The patient meets one of the following criteria: a) if the patient is 17 years of age or younger, the patient has experienced an inadequate treatment response or intolerance to at least one central nervous system (CNS) stimulant drug (e.g., amphetamine, dextroamphetamine, methylphenidate), OR has a contraindication that would prohibit a trial of central nervous system (CNS) stimulant drugs (e.g., amphetamine, dextroamphetamine, methylphenidate), b) If the patient is 18 years of age or older, the patient has experienced an inadequate treatment response or intolerance to at least one central nervous system (CNS) wakefulness promoting drug (e.g., armodafinil, modafinil), OR has a contraindication that would prohibit a trial of central nervous system (CNS) wakefulness promoting drugs (e.g., armodafinil, modafinil). For the treatment of cataplexy in a patient with narcolepsy, initial request: The diagnosis has been confirmed by sleep lab evaluation. If the request is for a continuation of therapy, then the patient experienced a decrease in daytime sleepiness with narcolepsy or a decrease in cataplexy episodes with narcolepsy. |
| <b>Age Restrictions</b>             | 7 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>Prescriber Restrictions</b>      | Prescribed by or in consultation with a sleep disorder specialist or neurologist                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | YESINTEK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | YESINTEK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | For moderate to severe plaque psoriasis (new starts only): 1) at least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) patient meets any of the following: a) patient has experienced an inadequate treatment response or intolerance to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine, or acitretin, b) pharmacologic treatment with methotrexate, cyclosporine, or acitretin is contraindicated, c) patient has severe psoriasis that warrants a biologic as first-line therapy (i.e., at least 10% of the body surface area or crucial body areas [e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas] are affected). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prior Authorization Group</b>    | YONSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | YONSA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Required Medical Information</b> | The requested drug will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or after bilateral orchiectomy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ZARXIO                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | ZARXIO                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Neutropenia in myelodysplastic syndromes (MDS), agranulocytosis, neutropenia in aplastic anemia, human immunodeficiency virus (HIV)-related neutropenia                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | If receiving chemotherapy, the requested drug will be administered at least 24 hours after chemotherapy. For prophylaxis or treatment of myelosuppressive chemotherapy-induced febrile neutropenia (FN) patient must meet both of the following: 1) Patient has a solid tumor or non-myeloid cancer, AND 2) Patient has received, is currently receiving, or will be receiving treatment with myelosuppressive anti-cancer therapy. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | 6 months                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prior Authorization Group</b>    | ZEJULA                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | ZEJULA                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Off-label Uses</b>               | Uterine leiomyosarcoma                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Required Medical Information</b> | For uterine leiomyosarcoma: 1) the requested drug is used as second-line therapy AND 2) the patient has BRCA-altered disease.                                                                                                                                                                                                                                                                                                       |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                   |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ZELBORAF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Drug Names</b>                   | ZELBORAF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Non-small cell lung cancer, hairy cell leukemia, central nervous system cancer (i.e., glioma, glioblastoma, pediatric diffuse high-grade glioma), adjuvant systemic therapy for cutaneous melanoma, Langerhans cell histiocytosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | For central nervous system (CNS) cancer (i.e., glioma, astrocytoma, glioblastoma, pediatric diffuse high-grade glioma): 1) The tumor is positive for BRAF V600E mutation, AND 2) The requested drug will be used in combination with cobimetinib OR the requested drug is being used for the treatment of pediatric diffuse high-grade glioma. For melanoma: 1) The tumor is positive for BRAF V600 activating mutation (e.g., V600E or V600K), AND 2) the requested drug will be used as a single agent, or in combination with cobimetinib, AND 3) The requested drug will be used for either of the following: a) unresectable, limited resectable, or metastatic disease, or b) adjuvant systemic therapy. For Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Tumor is positive for BRAF V600 mutation. For non-small cell lung cancer: 1) The tumor is positive for the BRAF V600E mutation, AND 2) The patient has recurrent, advanced, or metastatic disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prior Authorization Group</b>    | ZIRABEV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Drug Names</b>                   | ZIRABEV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Off-label Uses</b>               | Ampullary adenocarcinoma, appendiceal adenocarcinoma, breast cancer, central nervous system (CNS) cancers (including pediatric diffuse high-grade gliomas), pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, tunica vaginalis testis mesothelioma, soft tissue sarcomas, uterine neoplasms, endometrial carcinoma, vulvar cancers, small bowel adenocarcinoma, and ophthalmic-related disorders: diabetic macular edema, neovascular (wet) age-related macular degeneration including polypoidal choroidopathy and retinal angiomatous proliferation subtypes, macular edema following retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization, neovascular glaucoma and retinopathy of prematurity                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Other Criteria</b>               | Coverage under Part D will be denied if coverage is available under Part A or Part B as the medication is prescribed and dispensed or administered for the individual.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ZOLINZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Drug Names</b>                   | ZOLINZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Off-label Uses</b>               | Mycosis fungoides (MF)/Sezary syndrome (SS)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | ZONISADE                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Drug Names</b>                   | ZONISADE                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | For adjunctive treatment of partial-onset seizures (i.e., focal-onset seizures): 1) The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to a generic anticonvulsant AND the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to any of the following: Aptiom, Xcopri, Spritam OR 2) The patient has difficulty swallowing solid oral dosage forms (e.g., tablets, capsules). |
| <b>Age Restrictions</b>             | 16 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Prior Authorization Group</b>    | ZTALMY                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Drug Names</b>                   | ZTALMY                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Required Medical Information</b> | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | 2 years of age or older                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ZURZUVAE                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Drug Names</b>                   | ZURZUVAE                                                                                                                                                                                                                                                                                                                                                                              |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications                                                                                                                                                                                                                                                                                                                                                          |
| <b>Off-label Uses</b>               | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For the treatment of postpartum depression (PPD): diagnosis was confirmed using standardized rating scales that reliably measure depressive symptoms (e.g., Hamilton Depression Rating Scale [HDRS], Edinburgh Postnatal Depression Scale [EPDS], Patient Health Questionnaire 9 [PHQ9], Montgomery-Asberg Depression Rating Scale [MADRS], Beck's Depression Inventory [BDI], etc.). |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | 1 month                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prior Authorization Group</b>    | ZYDELIG                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Drug Names</b>                   | ZYDELIG                                                                                                                                                                                                                                                                                                                                                                               |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                     |
| <b>Off-label Uses</b>               | Small lymphocytic lymphoma (SLL)                                                                                                                                                                                                                                                                                                                                                      |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Required Medical Information</b> | For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): the requested drug is used as second-line or subsequent therapy.                                                                                                                                                                                                                                             |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                     |

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Prior Authorization Group</b>    | ZYKADIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>Drug Names</b>                   | ZYKADIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| <b>PA Indication Indicator</b>      | All FDA-approved Indications, Some Medically-accepted Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Off-label Uses</b>               | Recurrent anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), recurrent, advanced, or metastatic ROS1-positive NSCLC, Erdheim-Chester Disease (ECD) with ALK-fusion, inflammatory myofibroblastic tumor (IMT), brain metastases from NSCLC, relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL)                                                                                                                                                                                                                                                                    |
| <b>Exclusion Criteria</b>           | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Required Medical Information</b> | For non-small cell lung cancer (NSCLC): 1) the patient has recurrent, advanced, or metastatic anaplastic lymphoma kinase (ALK)-positive AND 2) the patient has experienced an inadequate treatment response, intolerance, or has a contraindication to ONE of the following products: Alecensa (alectinib) or Alunbrig (brigatinib) OR 3) ROS1-positive disease. For inflammatory myofibroblastic tumor: the disease is ALK-positive. For brain metastases from NSCLC: the patient has ALK-positive NSCLC. For anaplastic large cell lymphoma (ALCL): the patient has relapsed or refractory ALK-positive disease. |
| <b>Age Restrictions</b>             | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Prescriber Restrictions</b>      | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Coverage Duration</b>            | Plan Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Other Criteria</b>               | -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

Molina Healthcare is a C-SNP, D-SNP and HMO plan with a Medicare contract. D-SNP plans have a contract with the state Medicaid program. Enrollment depends on contract renewal.

**CHP Only:** Central Health Medicare Plan is an HMO/HMO SNP with a Medicare contract. Enrollment in Central Health Medicare Plan depends on contract renewal.

**NM D-SNP Only:** Such services are funded in part with the State of New Mexico.

<https://www.molinahealthcare.com/members/common/en-US/multi-language-taglines.aspx>

[https://centralhealthplan.com/Docs/Member/Multi\\_Lanugage\\_Insert.pdf](https://centralhealthplan.com/Docs/Member/Multi_Lanugage_Insert.pdf)

Molina Healthcare complies with applicable Federal civil rights laws and does not discriminate on the basis of age, color, disability, national origin (including limited English proficiency), race, or sex (consistent with the scope of sex discrimination described at § 92.101(a)).

To help you effectively communicate with us, Molina Healthcare provides services free of charge and in a timely manner:

- Molina Healthcare provides reasonable modifications and appropriate aids and services to people with disabilities. This includes: (1) Qualified interpreters. (2) Information in other formats, such as large print, audio, accessible electronic formats, Braille.
- Molina Healthcare provides language services to people who speak another language or have limited English skills. This includes: (1) Qualified oral interpreters. (2) Information translated in your language.

If you need these services, contact Molina Member Services at 1-800-665-3086 or TTY/TDD: 711, Monday to Friday, 8 a.m. to 8 p.m., local time.

If you believe we have discriminated on the basis of age, color, disability, national origin, race, or sex, you can file a grievance. You can file a grievance by phone, mail, email, or online. If you need help writing your grievance, we will help you. You may obtain our grievance procedure by visiting our website at <https://www.molinahealthcare.com/members/common/en-US/Notice-of-Nondiscrimination.aspx>

Call our Civil Rights Coordinator at 1-866-606-3889, TTY/TDD: 711 or submit your grievance to:

Civil Rights Unit  
200 Oceangate  
Long Beach, CA 90802  
Email: [civil.rights@molinahealthcare.com](mailto:civil.rights@molinahealthcare.com)  
Website: <https://molinahealthcare.Alertline.com>

You can also file a civil rights complaint (grievance) with the U.S. Department of Health and Human Services, Office for Civil Rights, online through the Office for Civil Rights Complaint Portal at: <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf> or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
Phone: 1-800-368-1019  
TTY/TDD: 800-537-7697

Complaint forms are available here: <https://www.hhs.gov/sites/default/files/ocr-cr-complaint-form-package.pdf>